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Abstract 
 
Osteoarthritis (OA), a degenerative disease of articular joints, is the leading cause of 
chronic disability in the US and affects more than a third of adults over 65 years old. Due to the 
obesity epidemic and an aging population, the prevalence of OA is expected to rise in both 
young and old adults. There are no disease modifying OA drugs. Therefore, providing any 
treatment options that delay the onset or progression of OA is highly desirable. The scope of 
this dissertation examines two different strategies to promote translational therapies for OA. The 
first approach investigated whether Smad ubiquitin regulatory factor 2 (Smurf2), an E3 ubiquitin 
ligase, could be a potential therapeutic target for OA. The second approach examined the 
incorporation of small chemical residues to enhance the physical and bioactivity of a bioinert 
scaffold for cartilage tissue repair.  
 Overexpression of Smurf2 in chondrocytes was shown to accelerate spontaneous OA 
development in mice. We hypothesized that reduced Smurf2 expression could slow the 
progression of OA and enhance the performance of cells for cartilage repair. By performing 
surgical destabilization of the medial meniscus (DMM) on Smurf2-deficient mice, loss of Smurf2 
was shown to mitigate OA changes in young mice but this protection diminished in older mice. 
Assessment of Smurf2-deficient chondrocytes in vitro revealed an upregulation of chondrogenic 
genes compared to wild-type; however, these differences were not seen at the protein level, 
deterring its potential use for cell-based therapies. During the course of this study, new insights 
about how age and sex affects different joint compartments in response to DMM surgery were 
also uncovered. These results broadened existing understanding of DMM-induced OA in mice 
but also questioned the validity of such a model to identify disease modifying targets that are 
translatable to OA in humans with advanced age. 
Due to a lack of innate repair mechanisms in cartilage, damage to cartilage increases 
the risk of developing OA early. Tissue engineering provides a unique strategy for repairing 
damaged cartilage by delivering cells in a well-controlled environment that can promote the 
formation of neotissue. We hypothesized that synthetic chemical residues could enhance the 
mechanical properties of a bioinert scaffold and promote matrix production of encapsulated 
chondrocytes. Covalent incorporation of small anionic or zwitterionic chemical residues in a 
polyethylene glycol-based hydrogel improved its stiffness and resistance to fluid flow, however, 
the resulting physical environment can also exert a dominant negative effect on matrix 
production of encapsulated chondrocytes. These results suggest that modulating the 
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biosynthesis of chondrocytes with biochemical signals requires a concurrent reduction in any 
conflicting mechanotransduction signaling, emphasizing the importance of a degradable system 
to promote new cartilage formation. 
In summary, this dissertation establishes Smurf2 as a modulator of OA progression but 
implies that other factors such as age or protein(s) with redundant Smurf2 functions may play a 
role in limiting its effect as a therapeutic target. This work also reveals fundamental biology 
about how chondrocytes behave in response to physical and chemical cues in their 
microenvironment, which will aid in the design of better scaffolds for cartilage tissue engineering. 
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Chapter I: Introduction 
 
 
1. Osteoarthritis (OA) 
 
Osteoarthritis (OA) is a degenerative disease of articular joints that leads to chronic pain 
and ultimately loss of function. It is characterized by articular cartilage degradation, subchondral 
bone sclerosis, osteophyte formation and varying levels of synovial inflammation. OA is the 
most common form of arthritis and is a major cause of chronic disability1. At the individual level, 
it affects functions of daily living and reduces quality of life; while on a population level, it 
remains a significant socioeconomic burden due to lost wages and increased healthcare 
expenditure2,3. Because age is the primary risk factor for OA development, the prevalence of OA 
is expected to rise as the human population continues to age. However, even among younger 
adults who are less than 65, hip and knee OA are on the rise as a result of the obesity epidemic 
and an increase in traumatic joint injuries4,5.  
In contrast to rheumatoid arthritis, which is ten times less prevalent than OA6 but has 
seen clinical success with numerous anti-inflammatory agents 7 , 8 , there are currently no 
regulatory approved disease-modifying OA drugs (DMOADs). Clinical management of OA 
focuses on physical therapy and exercise in order to build strength and increase tolerance for 
joint function. In the context of obesity, weight loss along with exercise has shown the most 
significant reduction in joint pain and enhancement of function 9 . Joint pain is also 
pharmacologically managed with acetaminophen and non-steroidal anti-inflammatory drugs 
(NSAID), followed by intraarticular injections of hyaluronic acid (HA) or corticosteroids. After 
these non-surgical options have been exhausted, total joint arthroplasty is recommended for 
patients with severe pain and joint deformity. While the positive outcomes of joint replacement 
on pain relief, quality of life and physical function among the elderly is well-established10,11, the 
need for DMOADs remains for the younger adults who are at higher risk for revision 
surgeries12,13 and can outlive the lifetime of their implants.  
 
 
2. Challenges in Developing Disease Modifying OA Drugs 
 
For years, the lack of research into DMOAD has been steered by the misperception that 
OA is a wear and tear disease caused by the natural aging process. Only in the past few 
decades have researchers acknowledged OA as a degenerative disease of the entire joint 
affecting multiple tissue compartments and involving numerous proinflammatory cytokines. 
While basic science research has uncovered many molecular signals involved in articular 
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cartilage degradation, subchondral bone sclerosis and synovial inflammation, the initiating 
factors and key regulators that drive disease progression remain poorly understood 14 . In 
addition, other challenges exist for the development of DMOADs, such as correlating imaging 
studies to disease progression and outcome measures, tackling the discrepancy between 
clinical symptoms and joint structure, and stratifying OA patients according to their disease 
presentation and clinical symptoms. 
Even though the diagnosis of OA is based on clinical symptoms (chronic pain, stiffness, 
instability), imaging techniques remain the most objective assessment of joint structure to 
confirm the diagnosis and to monitor disease progression. Plain radiographs are the most 
convenient and cost-effective modality to indirectly monitor articular cartilage destruction 
through progressive joint space narrowing 15 . However, it is increasingly evident that plain 
radiographs are less sensitive to detect early OA changes compared to magnetic resonance 
imaging (MRI) regardless of pain16. MRI has become a dominant imaging modality among the 
research community to test DMOADs, allowing unparalleled assessment of multiple joint 
structures, including cartilage loss, synovial inflammation, meniscal tears, osteophytes, and 
bone marrow lesions17. In addition, various scoring systems such as the Whole Organ Magnetic 
Resonance Imaging Score (WORMS)18, Boston Leed Osteoarthritis Knee Score (BLOKS)19 and 
the MRI Osteoarthritis Knee Score (MOAKS)20, have been developed over the years to provide 
semi-quantitative scores of OA-related changes detected on MRI. Although the responsiveness 
and reliability of MRI-based measurements of knee OA is being validated21, additional work is 
necessary to identify the key findings most predictive of OA severity and need for joint surgery22.  
Another fundamental issue with developing OA drugs is the discrepancy between joint 
structure and clinical symptoms. Since cartilage is not innervated, pain associated with OA is 
thought to be a result of synovial inflammation and effusion23. Meanwhile, joint space narrowing 
as measured by plain radiographs, remains the gold standard for assessing efficacy of 
DMOAD24, and it is unclear whether countering these structural changes confers clinical benefit 
of reduced pain or increased function. Bedson and Croft have proposed that better standardized 
protocols of taking x-rays of the joint and standardized definition of knee pain could improve the 
correlation between radiographic knee and pain but evidence of a strong correlation is lacking25. 
Therefore, it is more likely that clinical trials for OA therapy will be divided by drugs that relieve 
pain from those that modify joint structure. As the role of cytokines in OA pathogenesis 
becomes clearer and molecular crosstalks between structures are revealed, biological agents26 
targeting cytokines or growth factor receptors may eventually be effective at treating both pain 
and structural changes simultaneously. 
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Due to the multifaceted nature of OA and the presence of comorbidities, the disease 
impact and progression varies significantly among patients, and therapy should also be tailored 
accordingly. Numerous studies have utilized radiographic knee OA to stage disease 
progression27 , 28  and enhance its predictive value 29 , 30 , but there is an increasing need for 
biochemical markers to assess dynamic changes within the joint and to detect early signs of 
joint abnormalities. The utility of biomarkers for diagnosing OA and directing therapeutic 
strategies is profound31. Ideally, they could facilitate early diagnosis of OA, stratify patients 
according to different OA symptoms, act as a surrogate for clinical endpoints and assess patient 
responsiveness to particular therapies. Many proposed candidates for OA biomarkers are 
related to the metabolism and degradation of bone or cartilage, including telopeptides of type I 
and II collagen and cartilage oligomeric matrix proteins (COMP). While some of these have 
shown promise in early clinical trials32,33, none have shown sufficient discrimination to aid in the 
diagnosis or prognosis of individuals with OA34. With continuous advances in molecular biology, 
imaging techniques, and next generation sequencing, the phenotyping of OA patients can 
improve and clinical endpoint for pharmacotherapy can be better defined. 
 
 
3. Pathogenesis of OA 
 
Articular Cartilage, Chondrocytes, and Cartilage Matrix Degradation 
 
Although the pathogenesis of OA is multifactorial and its etiology remains largely unclear, 
the progressive destruction of articular cartilage remains a hallmark of the disease. Articular 
cartilage is a specialized tissue that lines the end of long bones. It provides a frictionless surface 
for movement and the mechanical forces to withstand compressive loads and shear forces. 
Articular or hyaline cartilage is a multiphasic tissue made up of 60-85% water, 15-20% of type II 
collagen, 4-7% of proteoglycan and only one cell type, the chondrocyte35. The distribution and 
orientation of these extracellular matrix (ECM) proteins and chondrocytes are highly dependent 
on their location within cartilage as defined by 4 different zones (superficial/tangential, 
transitional/middle, deep and calcified) (Figure 1.1). The superficial zone, which provides the 
most resistance to shear forces, is made up of collagen fibers and chondrocytes oriented 
parallel to the surface. In contrast, the transitional or middle zone layers contain a mixture of 
randomly oriented collagen fibers and proteoglycans, which provide optimum resistance to 
compressive and tensile forces. The relatively inactive metabolism of chondrocytes in the 
superficial zone, however, increases its susceptibility to fibrillations and allows shear forces to 
penetrate into deeper layers36. The deep and calcified zone contain collagen fibers oriented 
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perpendicular the surface and acts as an anchor for cartilage to the underlying subchondral 
bone and is thought to be an intermediary for force transmission between the two structures37. 
During OA, the presence of multiple tidemarks also suggests that calcified cartilage can 
advance towards the deep zone and contribute to the thinning of the hyaline cartilage above38. 
 
 
Figure 1.1 Depiction of chondrocyte and collagen fiber organization and the different zones in articular 
cartilage.  
(STZ = superficial tangential zone) Figure is reproduced with permission from Buckwalter JA, Mow VC, Ratcliffe A. 
Restoration of Injured or Degenerated Articular Cartilage. J Am Acad Orthop Surg. 1994 Jul;2(4):192-201. 
http://journals.lww.com/jaaos/Abstract/1994/07000/Restoration_of_Injured_or_Degenerated_Articular.2.aspx  
 
Resident chondrocytes, which are solely responsible for remodeling cartilage ECM, 
rarely undergo division after skeletal maturity and appear stable throughout adulthood. They 
maintain a low metabolic activity and low turnover rate of cartilage matrix proteins, with the half-
life of cartilage collagen calculated to be over 100 years39. As a consequence of aging40 or other 
stressors like mechanical injury or inflammation 41 , the health of chondrocytes can be 
jeopardized and the balance between ECM production and degradation becomes dysregulated.  
One evidence of this dysregulation is the phenotypic shift of resident chondrocytes towards 
hypertrophy, resulting in increased expression of type X collagen42 and proteolytic enzymes 
such as matrix metalloproteinases43 , 44 , 45  (MMP) and aggrecanases (ADAMTS) 46 , 47 . During 
embryonic and postnatal skeletal development, chondrocytes undergo hypertrophy and 
apoptosis as part of endochondral ossification, where cartilage ECM is calcified and remodeled 
into bone48. In the absence of disease, articular chondrocytes maintain their phenotype by 
inhibiting maturation, allowing them to produce the specific ECM proteins found in hyaline 
cartilage. Under aberrant conditions or stimuli, the adult resident chondrocytes are propelled 
towards terminal differentiation and apoptosis, initiating a seemingly irreversible signaling 
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cascade of cartilage degradation and mimicking the endochondral ossification process seen in 
development49. 
Signaling molecules driving chondrocyte hypertrophy have been identified from the 
creation of genetically-modified mice. While these factors do not demonstrate a causative effect, 
they provide insight and potential targets to reverse the hypertrophic chondrocyte phenotype. 
Many transcription factors have been shown to regulate chondrocyte hypertrophy (Figure 1.2A) 
such as runt-related transcription factor-2 (Runx2)50, hypoxia-inducible factor-2alpha (HIF-2α)51, 
Indian hedgehog (Ihh) 52 , beta-catenin (β-catenin) 53  and nuclear factor of activated T cells 
(NFAT)54. Among these, Runx2 is a master regulator of chondrocyte hypertrophy and is a 
downstream target of multiple signaling pathways, including transforming growth factor-beta 
(TGF-β) 55 , bone morphogenic protein (BMP) and Wnt/β-catenin 56  (Figure 1.2B). A shift in 
signaling activation from the TGF-β to the BMP pathway is thought promote chondrocyte 
differentiation and hypertrophy. E3 ubiquitin ligases, such as Smad ubiquitin regulatory factors 
(Smurf) have also been linked to modulating intracellular Smads downstream of TGF-β/BMP 
signaling and can modulate Runx2 expression (Figure 1.2B). Whether Smurfs are involved in 
driving OA pathogenesis through chondrocyte differentiation and hypertrophy is not as clear. 
Despite the involvement of these signaling molecules to drive chondrocyte hypertrophy, 
the exact cause of these aberrant signals remains unclear. Various stimuli, such as cartilage 
fragments caused by microtrauma or mechanical and oxidative stress57,58 from joint injury, are 
potential triggers for the release of proinflmmatory cytokines from synoviocytes and/or 
chondrocytes to initiate the OA process. Indeed, proinflammatory cytokines (such as interleukin-
859, S100 proteins60, and NFκB signaling61,62,63) have been shown to accelerate the hypertrophic 
phenotype of chondrocytes. An interesting hypothesis proposed by Blaney Davidson et al. is 
that age can cause a change in cell surface receptor expression on chondrocytes leading to 
abnormal downstream signaling64. They showed that an age-induced shift in activin-like kinase 
(ALK) receptors from ALK5 to ALK1 on mammalian chondrocytes resulted in TGF-β signaling 
activation via Smad1/5/8 to promote hypertrophy and MMP-13 expression65.  
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Figure 1.2 Overview of signaling pathways involved in chondrocyte hypertrophy. 
(A) Transcriptional factors that modulate chondrocyte phenotype and the associated proteins that are secreted. 
Figure is reproduced with permission from van der Kraan PM, van den Berg WB. Chondrocyte hypertrophy and 
osteoarthritis: role in initiation and progression of cartilage degeneration? Osteoarthritis Cartilage. 2012 
Mar;20(3):223-32. http://www.oarsijournal.com/article/S1063-4584(11)00332-3/abstract. (B) Regulation of 
downstream targets of the TGF-β superfamily affects chondrocyte hypertrophy. Figure is reproduced with permission 
from van der Kraan PM, Blaney Davidson EN, van den Berg WB. A role for age-related changes in TGFbeta signaling 
in aberrant chondrocyte differentiation and osteoarthritis. Arthritis Res Ther. 2010;12(1):201. 
https://arthritis-research.biomedcentral.com/articles/10.1186/ar2896 
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Other than the phenotypic shift towards hypertrophy, aging naturally introduces changes 
in both cartilage matrix and chondrocyte function that predisposes to OA development. With age, 
the number of proteoglycans and the size of aggregates decreases 66  and the covalent 
crosslinking of type II collagen increases due to accumulated advanced glycation end products 
(AGEs)67. The combination of the two results in a stiffer cartilage matrix with inferior mechanical 
properties to withstand compressive loads. In addition, aged chondrocytes also show a natural 
decline in synthetic function, and reduced sensitivity to growth factors such as insulin-like 
growth factor-1 (IGF-1)68 and TGF-β69,70. Like other aged cells, chondrocytes also exhibit signs 
of senescence, with telomere shortening and increased staining for β-galactosidase 
activity71,72,73. Mobasheri et al. coined the term chondrosenescence to define the age-dependent 
deterioration of chondrocyte function highlighting changes in calcium signaling, ion channels, 
and mitochondrial dysfunction in oxidative stress response 74 . Recently, both chondrocyte 
apoptosis 75 , 76  and autophagy 77  have also gained traction as essential contributors to OA 
cartilage pathology, but it remains unclear whether age alone results the dysfunction of these 
cellular programs prior to OA. Carames et al. have demonstrated a protective role of autophagy 
in normal cartilage, which becomes dysregulated with age and in a surgically-induced OA 
model78. These types of cellular programming could account for the observation that cellularity 
in articular cartilage declines with age79. Since apoptosis and autophagy are detected in early 
stages of OA80, they remain potential therapeutic targets for preventing the onset of OA. 
 
Subchondral Bone and Osteophytes 
 
Other than cartilage degradation, abnormal bone modeling also occurs in OA. 
Subchondral bone plate thickening81 and osteophyte formation82 are dominant features of OA 
pathology and can be detected on plain radiographs. However, the mechanisms behind these 
two bone changes are thought to be very different. 
The subchondral bone plate is the cortical bone directly beneath the calcified cartilage 
layer. Due to the close proximity of the subchondral bone to the overlying cartilage, both 
biochemical and mechanical crosstalks between these tissues have been thoroughly 
investigated 83 . Pan et al. used fluorescein-labeled tracer perfusion and photobleaching 
techniques to show that small nutrients and signaling molecules can diffuse between articular 
cartilage and the subchondral bone84. Older studies have also detected structural defects and 
signs of vascular invasion that connects subchondral bone to articular cartilage85 , 86 . Bone 
marrow lesions that can be detected on MRI are also more localized to areas of severe cartilage 
damage 87 . These studies debunk the previous notionthat calcified cartilage serves as an 
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impenetrable barrier for nutrients and biochemical signals between the two structures 88 . 
Mechanical loading also directly affects both cartilage and subchondral bone, causing 
microcracks and splitting at the interface. Under repetitive microinjuries and mechanical 
weakening of the overlying cartilage, subchondral bone responds to the altered stimulus by 
initiating a faulty repair process. Although the overall bone volume appears to increase 
(sclerosis) as part of the repair process, mechanical testing of the scleroic subchondral bone 
plate suggest a weaker structure with lower bone mineral density89. Whether this faulty repair 
process is driven by cytokine signaling from hypertrophic chondrocytes or inflamed synoviocytes 
or abnormal mechanical loading, evidence has accumulated that subchondral bone osteoblasts 
are also dysfunctional. Primary human osteoblasts derived from OA subchondral bone show 
elevated alkaline phosphatase activity90, osteocalcin90, IFG-191  and reduction in parathyroid 
hormone (PTH) receptors92. Cytokines, prostaglandins and growth factors produced from these 
sclerotic osteoblasts can further target chondrocytes and exacerbate the degenerative process 
in the overlying cartilage93,94. These close interactions and interplay between cartilage and 
subchondral bone have led to the well-accepted concept of a bone-cartilage or osteochondral 
unit95,96,97, in which the perturbation of one structure ultimately affects the function of the other. 
Osteophytes are cartilaginous-bony outgrowths that are often localized to the periphery 
of the joint near the junction between cartilage and bone. The term osteophyte also 
encompasses the term chondrophyte, which refers to outgrowths that are predominantly 
composed of cartilage matrix. Unlike subchondral bone, it is unclear whether osteophytes have 
a functional role or if they develop secondary to other degenerative changes in the joint. One 
hypothesis is that osteophytes counter the mechanical instability in a diseased joint by pushing 
against slackened ligaments or limiting range motion98,99. However, conflicting evidence also 
suggests that osteophytes develop independently from other changes in the joint. For instance, 
in both mouse and dog models of OA, osteophyte formation can be detected as early as 2-3 
days after OA induction100,101. Nevertheless, a number of clinical studies have confirmed a 
greater association with disease severity based on the presence and size of the osteophyte 
alone102,103,104. Osteophytes are thought to derive from mesenchymal progenitor cells in the 
periosteum or synovium in response to abnormal mechanical loads105. Although a number of 
different characterization105, scoring criterion106 and classification107 of osteophytes have been 
performed, it remains a challenge to histologically assess osteophytes in humans and to 
correlate it with other degenerative changes. Nevertheless, osteophytes can contribute to joint 
pain through invasion of nerves through the marrow-like cavity and limit movement in OA 
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patients, so therapies that inhibit their formation could still relieve symptoms and maximize 
function. 
 
 
Synovial Inflammation and Proinflammatory Cytokines 
 
In healthy joints, the synovium is responsible for producing lubricin and hyaluronic acid 
(HA). They are the major components of the synovial fluid, which help protect cartilage108, 
provide a frictionless surface109 and regulate chondrocyte activity110,111. When the synovium 
becomes inflamed, inflammatory cytokines and proteolytic enzymes are released into the 
synovial fluid and can drive chondrocyte catabolism. Synovitis is detected in both early and late 
OA112 and is thought to contribute to both pain113,114 and OA progression115. Historically, OA is 
not considered an inflammatory arthritis like RA due to a lack of immune cells in the synovial 
fluid and synovium, but the effects of proinflammatory cytokines on OA pathology has 
increasingly become evident116. Several key catabolic cytokines that are upregulated in OA 
include interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and 
interleukin-8 (IL-8)117,118. 
The impact of IL-1β activity in the joint is extensive and detrimental, partly because 
chondrocytes, osteoblasts and synoviocytes can all produce and respond to it during 
inflammation. In vitro culture of human chondrocytes shows that IL-1β is a potent inhibitor of 
cartilage matrix synthesis by reducing type II collagen and aggrecan and increasing proteolytic 
enzymes like MMP-3 and MMP-13119,120,121. Furthermore, the cell surface receptors for IL-1β are 
increased in both OA chondrocytes 122  and synovial fibroblasts 123 , implying an increased 
sensitization to the catabolic effects of IL-1β. IL-1β also has a significant impact on regulating 
other cytokines and growth factor signaling. IL-1β can stimulate the production of IL-6124 and IL-
8 125 , which further tips the balance of cartilage matrix proteins towards catabolism and 
enhances the inflammatory process. IL-1β can also counter the anabolic effects of TGF-β 
signaling by increasing the inhibitory protein, SMAD7 and reducing TGF-β receptor 
expression126.  
TNF-α, like IL-1β, is also a major cytokine involved in OA pathogenesis. Because they 
share the same downstream signaling pathway that leads to NFκB activation63, TNF-α also 
inhibits chondrocyte synthesis of type II collagen 127  and proteoglycans 128 . They can also 
modulate mitochondrial function129 and increase production of reactive oxygen species130,131. 
Compared to IL-1β, TNF-α is less effective and less potent at inducing an inflammatory 
response and does not cause significant proteoglycan loss in vivo132. However, a combination of 
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these two cytokines is found to be synergistic at recruiting leukocytes to the synovium132.  
Another study also found that TNF-α and IL-1β inhibits the migration of chondrogenic progenitor 
cells in vitro, highlighting a new role for these cytokines to impair the cartilage healing process133. 
The production of IL-6 and IL-8 are most likely a consequence of IL-1β activity134 but can 
also be induced by advanced glycation end products135. While these cytokines share similar 
effects such as promoting cartilage catabolism136,137 and recruiting inflammatory cells to the 
synovium137,138, other conflicting evidence exists about their exact role. For instance, knocking 
out IL-6 resulted in more advanced OA with age or in a collagenase-induced OA model139. A 
possibility is that IL-6 could have some proanabolic and anti-inflammatory effects in early OA 
but may alter with age or at different stages of the disease. IL-6 is also thought to be an 
important cytokine in regulating osteoblast physiology140. Application of nonphysiological loads 
on osteoblasts derived from osteophytes induces both IL-6 and IL-8 production, suggesting that 
osteophytes could contribute to OA pathology through an inflammatory process141.  
 
 
4. Clinical Trials of Potential OA Drugs 
 
It is clear that many overlapping signaling pathways and joint structures are involved in 
OA (Figure 1.3). Through the use of genetically-modified mice, many potential targets for 
DMOADs have been proposed. These targets range from modulating chondrocyte behavior 
(catabolism, anabolism, metabolism, and differentiation), to remodeling subchondral bone and 
inhibiting synovial inflammation. Unfortunately, very few of these have yet to progress to larger 
animals or preclinical human trials. While the lack of a specific enough small molecule drug 
could be a limiting factor, unimpressive clinical results have also deterred the translation of our 
mechanistic understanding of OA to clinical therapies.  
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Figure 1.3 Overview of signaling pathways and structural changes in the development of OA. 
ADAMTS=a disintegrin and metalloproteinase with thrombospondin-like motifs. IL=interleukin. MMP=matrix 
metalloproteinase. TNF=tumour necrosis factor. IFN=interferon. IGF=insulin-like growth factor. TGF=transforming 
growth factor. VEGF=vascular endothelial growth factor. Figure is reproduced with permission from Glyn-Jones S, 
Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. Lancet. 2015 Jul 25;386(9991):376-
87. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60802-3/abstract  
 
 
One major setback has been the lack of clear evidence that anti-inflammatory biologics 
can modulate OA progression in humans. It is well-established that proinflammatory cytokines 
like TNF-α and IL-1β are key mediators of chondrocyte dysfunction and cartilage loss. Blocking 
IL-1β activity in animal OA models also showed chondroprotective effects142 , 143 . However, 
human clinical trials comparing IL-1 receptor antagonists to placebo showed some pain relief in 
knee OA but no improvement in function as determined by the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) scores 144 . In another study, human monoclonal 
antibody to IL-1 receptor type I also showed a non-significant but numerical improvement in 
pain145. Further optimization in dosing strategy or extending the half-life of the protein could yield 
different clinical results. Also, inhibitors of IL-1β may also be more effective in a subset of OA 
patients with more severe pain and signs of inflammation. 
On the other hand, there is an increasing effort from the clinical side to use existing 
small molecule drugs or biologics to target known degenerative changes in the joint. For 
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instance, many drugs used for the treatment of osteoporosis are being investigated as potential 
treatment for OA. Since subchondral bone remodeling in OA parallels osteoporosis in that it 
results in a mechanically weak bone with low mineral density, antiresorptive agents like 
bisphosphonates are being evaluated as a potential DMOAD146. The disease modifying effects 
of bisphosphonates was demonstrated in a surgically-induced OA rat model147 , but not in 
studies using a spontaneous OA guinea pig model 148 , 149 . Several human prospective 
randomized clinical (RCT) trials showed that risedronate reduced markers of cartilage 
degradation like CTX-II and NTX-1 but with no improvement in WOMAC scores or structural 
changes150,151. Clinical benefit was observed in one study, showing that maintaining low levels of 
CTX-II with risedronate for six months lowered risk of radiographic progression at 24 months152. 
Another drug that is used to treat severe osteoporosis in other countries but not the US is 
strontium ranelate. Clinical trials using strontium ranelate showed clinically meaningful 
improvements in pain as well as joint function153, but the drug’s risk for cardiovascular events 
such as myocardial infarction and venous thromboembolism should be carefully addressed. 
Statins, which are a class of cholesterol lowering drugs, are also hypothesized to be a 
potential DMOAD by regulating metabolically-induced inflammation in OA154. Since existing data 
associating statin use with incidence of OA are inconclusive155,156, a prospective randomized 
clinical trial evaluating atorvastain on OA progression is currently ongoing in Australia157.  Other 
drugs that have been tested in humans but failed to reach a meaningful clinical endpoint include 
doxycycline158,159, vitamin D supplementation160, and salmon calcitonin161. 
 
 
5. Spontaneous and Induced Mouse Models of OA 
 
Basic science research investigating potential molecular targets for DMOADs rely on 
genetically-modified mice to tease out the molecular signals involved in OA. While no OA 
mouse model fully recapitulates the human OA exactly, the similarities in disease manifestation 
are sufficient to uncover potential modulators. Mice colonies are relatively easy to maintain and 
expand and are much more affordable to achieve statistically significant results than larger 
animals. Ninety-nine percent of mouse genes match to the human genome162, and the shorter 
lifespan of mice makes them ideal for conducting age-related studies. Over the years, a number 
of different strategies have been developed to study OA progression in mice. They can be 
divided into spontaneous and induced models, with the latter being subdivided into non-surgical 
and surgical interventions.   
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Mice strain with spontaneous OA.  
 
Many inbred mice show a natural tendency to develop OA with age, but the incidence 
and severity of the disease varies widely with the strain, highlighting the importance of genetic 
risk factors in OA development. The STR/ort strain is the most commonly studied mouse for 
spontaneous OA and shares the same degenerative joint changes as humans163. The parental 
CBA strain, which does not develop spontaneous OA, serves as an effective control. While the 
advantage of such a model is that it mimics the slow progression of primary OA in humans, it is 
also more susceptible to varying outcomes of incidence and severity and requires a larger 
number of animals to power a study164. Other phenotypes such as obesity165, hepatomas, and 
altered metabolism (hypercholesterolemia, hyperlipidemia, anemia)166 that are not observed in 
the CBA strain can also confound the interpretation of specific causal relationships in this OA 
model. Since the STR/ort strain results in predictable and distinct stages of OA development, it 
could be beneficial for evaluating new therapeutic agents. However, the duration of treatment 
ranging from 8-30 weeks could be a discouraging factor167. 
 
 
Genetically modified mice with OA-like symptoms 
 
The ease of manipulating the mouse genome has led to numerous transgenic mice that 
develop an OA-like phenotype. In most cases, this involves knocking out a gene or knocking in 
a constitutively active gene that is suspected to be involved in OA development. Because the 
exact phenotype is not predictable, extensive biochemical and histological characterization is 
necessary to understand the exact pathology and determine whether it relates to OA. Several 
cartilage-specific genes that accelerate a spontaneous OA-like phenotype include knockouts of 
type IX collagen168, peroxisome proliferator-activated receptor gamma (PPARγ)169, von Hippel–
Lindau gene (Vhl)170, and constitutive expression of genes like MMP-13171. In cases where no 
age-dependent OA phenotype is observed such as in TGF-β receptor172, fibroblast growth factor 
receptor 1 (FGFR-1)173 or ADAMTS-4 and -5174,175 knockout mice, other strategies to induce 
‘secondary’ OA are required. 
 
 
Non-surgical induction of OA 
 
Non-surgical induction of OA typically refers to intraarticular injection of a chemical agent 
like monosodium iodoacetate (MIA) developed by Kalbhen 176  or a catabolic agent like 
collagenase.  An advantage of using these injections is the ability to induce OA in any joint, and 
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they can easily be applied to other non-rodent species. MIA is an inhibitor of glycolysis and is 
thought to initiate OA rapidly through its cytotoxic effect on chondrocytes. Histological analysis 
of knee joints a week after single injection of MIA shows severe chondrocyte death and collapse 
of cartilage structure, but synovial inflammation and subchondral bone changes were less 
apparent177. Due to its non-physiological mechanism and accelerated OA phenotype, the use of 
MIA for studying OA progression is no longer favored. More recently, MIA was used in mice178 
and rats179,180 to evaluate OA pain as measured by tactile allodynia, asymmetric weight bearing 
and forced ambulation.    
Unlike MIA, collagenase-induced OA has a latency period in which proteoglycan 
synthesis is maintained during the first month, followed by progressive degradation of the 
cartilage structure181. The differences in timing and severity of affected structures suggest a 
difference in etiology between these two methods. Collagenase indirectly causes joint instability 
by damaging type I collagen and increases the laxity of ligaments and tendons surrounding the 
joint182. On the other hand, like MIA, collagenase fails to induce a strong inflammatory response 
in the synovium, with symptoms resolving within 1 week and a lack of IL-1 activity thereafter183. 
Therefore, while much more gradual at inducing OA, collagenase may not reflect some of the 
major cytokines players involved in human OA. 
Although not as popular among researchers, non-invasive injury is another non-surgical 
induction of OA that is gaining interest over the years. These include intra-articular fracture of 
the tibial subchondral bone 184 , cyclic tibial compression loading 185 , and anterior cruciate 
ligament (ACL) rupture via tibial compression186. A major advantage of this type of OA model is 
to mimic the mechanical traumas seen in human joints such as motor vehicle accidents or in 
sports-related ACL tears. These aseptic techniques allow assessment of early inflammatory and 
cellular response and avoid the skin incision and capsulotomy, which are required for surgically-
induced models187. Because these methods are still in their infancy, emphasis should be placed 
on reproducibility, proper controls and correlation to human OA. 
 
 
Surgical induction of OA 
 
Surgical induction of OA combines joint destabilization, intraarticular inflammation and 
abnormal contact between cartilage surfaces to reflect a post-traumatic state. Surgical models 
were initially developed in larger animals such as the anterior cruciate ligament transection 
(ACLT) in dogs188 and the partial meniscectomy in rabbits189. These techniques were later 
applied to small animals like rats190 and guinea pigs191. Compared to non-invasive injuries, 
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surgical injury models are more precise in that they create specific cuts and damage to 
ligament(s) and/or the meniscus. However, gaining access inside the joint is an additional 
burden to the animal. Furthermore, performing the surgery often requires proper training and 
practice with microsurgical tools and the reproducibility among researchers is a concern. 
The earliest surgical induction of OA in mice was described by Visco et al. using a partial 
medial meniscectomy and medial collateral ligament transection 192 . Using this technique, 
Clements et al. showed that loss of IL-1β and IL-1β-converting enzyme led to an accelerated 
OA after surgery193. This was soon followed by Kamekura et al. who demonstrated that the 
severity of OA progression after surgery can be modulated by the severity of the injury (i.e 
number of transected ligaments and involvement of the meniscus)194. In their study they focused 
on ACLT and how the addition of other ligament transection and/or meniscectomy accelerated 
the OA phenotype post-surgery (Figure 1.4). The combination of these different surgical 
procedures allows assessment of different stages of OA without needing to wait for disease 
progression. 
In comparison to ACLT, Glasson et al. proposed a new surgical instability model that 
involves destabilization of the medial meniscus (DMM) by transecting the meniscotibial ligament 
(shown in green in Figure 1.4)195. Their results show that DMM results in a mild OA phenotype 
with a reproducible cartilage lesion in the center of the medial tibial plateau. Moreover, the 
peripheral nature of the meniscotibial ligament makes the surgery much easier to perform than 
ACLT. Over the years, the DMM model has become a gold standard for studying OA onset and 
progression in many transgenic mice196. Potential therapeutic agents such as rapamycin197, 
resveratrol198, proteasome inhibitor MG132199 and kartogenin200 have all been demonstrated to 
inhibit OA progression in the DMM model. 
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Figure 1.4 Diagram of mouse knee and the combination of ligament transections and meniscectomy needed 
to induce different severity of OA. 
PL=patellar ligament. MM=medial meniscus. LM=lateral meniscus. MCL=medial collateral ligament. LCL=lateral 
collateral ligament. ACL= anterior cruciate ligament. PCL=posterior cruciate ligament. MMTL=medial meniscotibial 
ligament. DMM=destabilization of the medial meniscus surgery. Figure is adapted from Kamekura S, Hoshi K, 
Shimoaka T, Chung U, Chikuda H, Yamada T, Uchida M, Ogata N, Seichi A, Nakamura K, Kawaguchi H. 
Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis 
Cartilage. 2005 Jul;13(7):632-41.  
 
 
 
6. Tissue Engineering Strategies to Repair Articular Cartilage Defects 
 
 
Post-traumatic OA and Articular Cartilage Damage 
 
OA that develops after a documented incident resulting in articular fracture, cartilage or 
meniscal damage is termed post-traumatic OA. Approximately 12% of all symptomatic OA is 
estimated to be post-traumatic OA201.  Even though the progression to OA after an injury is 
poorly documented, patients who develop post-traumatic OA are on average 10 years younger 
MMTL
DMM
Mild
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than those who develop primary OA201. This gap between joint injury and OA onset is a potential 
window of opportunity for medical therapy to intervene.  
However, treating articular cartilage damage is a clinical challenge due to the lack of 
innate repair mechanisms. Cartilage lesions are categorized as non-structural (alterations in 
composition of matrix proteins), partial thickness, full thickness (subchondral bone surface is 
exposed), or osteochondral (if the subchondral bone is also damaged) 202 . Unlike the 
degenerative changes seen in OA, chondral defects are usually focal, well-defined and 
surrounded by healthy tissue. These defects are often a result of blunt-force trauma 
experienced during sports or accidents 203 . Regardless of whether the defect heals 
spontaneously or heals through bone marrow stimulation (microfracture)204, the result is a type I 
collagen-rich fibrocartilage that does not confer the same mechanical or lubricating properties 
as hyaline cartilage. Eventually, fibrocartilage also degrades and progressive damage 
originating from the initial lesion will accelerate OA development 205 . Therefore, the ideal 
treatment for cartilage lesions is still to promote cartilage regeneration206 or at the very least, to 
inhibit progressive damage by resurfacing the defect with a matrix similar in composition and 
mechanical strength to hyaline cartilage.  
 
 
Cartilage Tissue Engineering 
 
Tissue engineering is an interdisciplinary approach to replace or regenerate tissue using 
a combination of cells, biomaterials and/or bioactive molecules207. Whether there is a limited 
healing capacity or a defect in the repair process (caused by disease or trauma), tissue 
engineering attempts to overcome these challenges by enhancing innate repair processes, 
facilitating the growth of new tissue in situ, or delivering a tissue-like structure that was grown ex 
vivo. For cartilage tissue engineering, this often involves progenitor cells that recapitulate the 
developmental process of new cartilage formation 208 , biomaterials that exhibit mechanical 
strength similar to native cartilage or function as a bioactive template for regenerative processes, 
or pre-assembled chondral/osteochondral-like constructs that is implanted and integrated with 
neighboring tissue209. The immune privileged site of cartilage and the misconception that it is a 
relatively homogenous structure led many to believe that the success of cartilage tissue 
engineering was inevitable. Early work by Freed et al. showed that bovine chondrocytes seeded 
on a synthetic porous scaffold in vitro and in vivo produced a cartilage-like ECM (dominated by 
type II but not type I collagen)210. Since then, many new biomaterials have been developed, 
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alternative cell types such as stem cells have been investigated, and fundamental biology 
relating to chondrogenesis and chondrogenic differentiation have been uncovered. 
Despite these advances in research, over two decades have passed and the only clinical 
progress for cartilage repair is in autologous chondrocyte implantation (ACI) that Brittberg et al. 
pioneered211. To effectively translate cartilage tissue repair research to clinical therapies, many 
challenges and unanswered questions need to be addressed212. Some of these involve 1) 
determining the cell type most suitable for producing hyaline cartilage but which can also be 
expanded to sufficient quantity 213 , 2) scaling up scaffolds without compromising nutrient 
diffusion214, 3) determining whether recapitulating zonal architecture of cartilage is necessary for 
long-term function and stability215, 4) facilitating integration of neocartilage with native tissue216, 
and 5) overcoming regulatory restrictions on introducing new cell-biomaterial constructs in 
humans217,218. 
 
 
Natural versus Synthetic Hydrogels 
 
Hydrogel is an attractive material for cartilage tissue engineering due to its innate water 
absorbing capacity that is reminiscent of native cartilage. The ability of hydrogels to encapsulate 
cells within a 3D network can also maintain their spherical morphology and prevent 
dedifferentiation219. Hydrogels derived from both natural and synthetic polymers have been 
explored for cartilage tissue engineering and each has its own advantages and disadvantages.  
The inspiration behind natural polymer-based hydrogels is to mimic macromolecules 
found in native cartilage, such as collagen 220 , 221 , hyaluronic acid (HA) 222 , and 
glycosaminoglycans (GAGs)223. As a result, these macromers are inherently biocompatible and 
possess many bioactive cues that assist in directing encapsulated cells’ behavior. Even though 
covalent chemical modifications of these macromers are often required to create a gelation 
reaction through photopolymerization224 or click chemistry225, the degree of modification is often 
poorly controlled and characterized. Other disadvantages of these natural hydrogels are their 
mechanically weak structure and their poorly controlled rates of degradation226. 
On the other hand, hydrogels derived from biocompatible synthetic polymers such as 
poly(ethylene) glycol are versatile and can be easily manipulated to achieve different 
mechanical or chemical properties or 3D printed into different shapes and structures. The 
incorporation of ester-containing polymers such as polyglycolic acid (PGA) and 
polycaprolactone (PCL) also introduce tunable rates of degradation into the hydrogel to 
hypothetically match the formation of neotissue from encapsulated cells. While the advantage of 
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being biocompatible renders these polymers biologically inert, these hydrogels are often 
combined with growth factors227 or native cartilage macromolecules in order to enhance their 
bioactivity228. 
 
 
Cell Types 
 
 Since chondrocytes are the only cells that reside in cartilage and are solely responsible 
for producing and maintaining cartilage ECM, it is intuitive to use them for cartilage repair. 
Currently, ACI is the only FDA-approved cartilage repair technique that has shown promise for 
producing hyaline-like matrix. The procedure involves harvesting autologous chondrocytes from 
a non-weight bearing location, expanding them in vitro, then implanting the cells mixed with a 
collagen-rich solution and covering the defect site with a periosteal autograft211. The main 
advantage of autologous chondrocytes is the lack of immune rejection from the host, but 
harvesting chondorcytes requires another surgical procedure and the donor site can lead to 
additional morbidity in patients229. Due to the low number of chondrocytes at time of harvest, in 
vitro expansion of these cells is required to achieve sufficient quantify for a larger defect site. 
However, primary chondrocytes tend to ‘dedifferentiate’ or lose their chondrogenic phenotype 
when expanded in 2D tissue culture plates (TCPS)230 and will most likely lead to fibrocartilage 
after implanation.   
In order to overcome the limitations of autologous chondrocytes, an alternative cell type 
for cartilage tissue repair is the stem cell. A potential source of stem cells in adults is the bone 
marrow. Bone marrow stromal cells (BMSC), sometimes referred to as mesenchymal stem cells 
(MSC), were first isolated by Freidenstein et al.231 and later characterized to show trilineage 
differentiation into adipocytes, osteocytes and chondrocytes 232 . Successful repair of an 
osteochondral defect in rabbits was performed by Wakitani et al. using autologous BMSCs and 
a collagen gel233. They demonstrated successful tissue repair with BMSCs differentiating into 
chondrocytes and undergoing endochondral ossification to restore the subchondral bone. More 
importantly, their results suggested that in vitro expansion of BMSCs did not lead to a loss of 
differentiation potential. Many tissue engineering studies soon followed to investigate BMSCs 
growth and differentiation with many biomaterials234 and in combination with growth factors such 
as TGF-β235,236,237 and BMP238 to aid in differentiation and matrix production. Other properties of 
BMSC that aid in tissue repair process include hypoimmunogenicity239, immunosuppresion240 
and chemotaxis241. 
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Although research interest in stem cells has grown exponentially, it is unclear whether 
the tissues grown from stem cells are any different than those grown from chondrocytes. A 
small study by Nejadnik et al. compared cartilage repair using autologous chondrocytes or 
BMSCs and showed that both groups had similar tissue composition and comparable 
improvement in patient function242. However, patient age appears to affect outcomes measures 
in the chondrocyte group, but not in the BMSC group, suggesting that age may impair 
chondrocyte function more easily than stem cells. While the replacement of autologous 
chondrocytes with BMSCs seem inevitable in the future due to accessibility of bone marrow, 
multilineage potential, and simplification of surgical procedure, many challenges still remain for 
BMSCs. For one, the precise control of BMSC differentiation is critical for cartilage repair since 
over differentiation could result in a hypertrophic phenotype 243  or an undesired cell type. 
Isolation of BMSCs through plastic adherence results in a heterogeneous population that can 
also affect culture expansion and differential potential244 . Cell surface markers are heavily 
studied to help enrich for a more homogenous stem cell population245 but the ideal profile for 
BMSCs has yet to reach consensus among researchers. 
 
 
Biochemical, Mechanical and Other Cues that direct Chondrocyte Behavior 
 
Hydrogels derived from synthetic polymers are biocompatible but at the same time also 
bioinert. In order to enhance the healing properties of cells delivered within them, bioactive 
molecules are often incorporated to prompt cell differentiation or augment matrix production. 
Bioactive molecules can range from proteins like cytokines and growth factors246 to smaller 
chemical molecules, peptides247 or nano-sized particles248,249,250. Growth factors such as TGF-
β251, BMP252, IGF-1253, and fibroblast growth factor (FGF)254 are frequently co-delivered with 
hydrogels to enhance chondrogenesis. Native biomacromolecules such as chondroitin sulfate 
and hyaluronic acid are also thought to be prochondrogenic due to their unique chemical 
composition that facilitates cell-matrix interaction and enriches secreted growth factors. 
Peptides containing the arginine-glycine-aspartic Acid (RGD) motif are also frequently tethered 
onto biomaterials to enhance cell attachment via integrin binding. Even though RGD motifs can 
facilitate chondrocyte attachment and proliferation, evidence also suggests that too much 
incorporation can alter their rounded morphology and lead to decreased ECM production255.  
Dynamic mechanical loading also play a critical role in modulating chondrocyte behavior. 
Given that the joint experiences stresses from 10-20 MPa on a daily basis, deformation of 
cartilage and the chondrocytes is essential to distribute the load and reduce contact stress256. 
 21 
Mechanical loads, either applied directly257 or in the form of hydrostatic pressure258, have been 
shown to modulate chondrocyte metabolism and matrix synthesis. They are also frequently 
used to enhance tissue engineered cartilage constructs ex vivo via a bioreactor259. Mechanical 
stimulation can also be combined with anabolic growth factors for synergistic effects260. Along 
the same lines, the interaction between material and chondrocytes can also induce mechanical 
signal transduction or alter metabolic activity in order to direct chondrocyte behavior. 
Chondrocytes cultured on stiffer materials produce less ECM than those cultured on softer 
matrices261,262. However, one study also suggests that chondrocytes prefer an optimal material 
stiffness (~0.5 MPa) for chondrogenesis263, highlighting the need to establish sufficient structural 
support for chondrocytes at time of implant. Furthermore, this mechanical integrity of the 
scaffold will need to be maintained during competing processes of ECM matrix production and 
scaffold resorption.  
Finally, oxygen tension also plays a role in chondrocyte behavior. Since cartilage is 
avascular, chondrocytes reside in a hypoxic environment with oxygen levels ranging from 7% 
near the surface to 1% near the subchondral bone264. Chondrocytes cultured in a hypoxic 
environment (5%) shows enhanced chondrogenesis and reduced catabolic gene expression 
compared to normoxic conditions (20%)265. This is most likely due in part to reduced nitric oxide 
(NO) production264, a mediator of proinflammatory cytokines in the joint, and upregulation of 
HIF-1α 266 , which directly affects chondrocyte metabolism, matrix production and 
differentiation267. 
 
 
7. Overview of Dissertation 
 
OA is a significant burden on an aging population and contributes to reduced quality of 
life and increased healthcare spending. Because no current DMOADs exist, there is a 
desperate need to identify new targets and therapies that can delay the onset or progression of 
OA and postpose joint replacement.  
This dissertation examines two parallel strategies to promote translational therapies for 
OA. Chapter II investigates whether Smad ubiquitin regulatory factor 2 (Smurf2), an E3 ubiquitin 
ligase, is required for OA pathogenesis and whether it is a viable target for DMOADs. Since 
Smurf proteins (Smurf1 and Smurf2) have been identified as a modulator of Smad proteins in 
TGF- signaling, it was hypothesized that knock down of Smurf2 could perturb the behavior of 
chondrocyte and/or osteoblast phenotype in vivo. In addition, Smurf2 has been implicated as a 
regulator of senescence and could potentially modulate age-dependent factors that drive OA 
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pathogenesis. Skeletal characterization of Smurf2-deficient (MT) mice were compared with wild-
type mice in an age-dependent manner and in a surgically-induced OA model. MT primary 
chondrocytes were also characterized to determine if the balance between cartilage matrix 
synthesis and degradation under chondrogenic and proinflammatory environments were 
perturbed compared to WT mice. Young MT mice showed milder cartilage OA damage after 
DMM surgery compared to age-matched WT. However, this protective effect was diminished in 
the older mice. MT primary chondrocytes expressed higher levels of chondrogenic mRNA 
compared to WT in vitro, but the difference was not detected at the protein level. These results 
highlight a potential role of Smurf2 to modulate OA but suggest that age-related factors or 
proteins with redundant Smurf2 function may limit the therapeutic efficacy of Smurf2 inhibition 
alone.  
Due to the differences observed in cartilage degradation between young and old mice 
after DMM, Chapter III takes a deeper look at the structural changes in the knee joint post DMM 
with respect to both age and sex. Using a combination of histology and microCT, this chapter 
highlights how age modulates the structural changes of different tissue compartments in 
response to DMM surgery. The susceptibility of female mice to DMM-induced OA is also 
increased with age but compared to male mice, they remain protected up to 18 months of age. 
These results supplement existing knowledge about DMM-induced OA in mice but also question 
the validity of such a model to identify disease modifying targets that is translatable to primary 
OA in humans. 
In Chapter IV, we turn towards tissue engineering strategy of repairing articular cartilage 
lesions. Because unrepaired focal articular cartilage lesions increase the risk of developing OA 
early, promoting hyaline cartilage formation in these defect sites using a cartilage tissue 
engineering approach could delay the onset of OA. A challenge with using synthetic hydrogels 
as a scaffold is balancing the mechanical strength to resist compressive loads without 
compromising nutrient transport and inhibiting chondrogenesis of encapsulated cells. This 
chapter investigates whether incorporation of synthetic chemical residues into a bioinert 
hydrogel could enhance its mechanical properties and promote matrix production by 
encapsulated chondrocytes. Covalent incorporation of small anionic or zwitterionic chemical 
residues in a polyethyleneglycol-based hydrogel improved its stiffness and resistance to fluid 
flow; however, at a certain incorporation content, the resulting stiffer environment also exerted a 
dominant negative effect on matrix production. These results suggest that modulating the 
biosynthesis of chondrocytes with biochemical signals may requires a concurrent reduction in 
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conflicting mechanotransduction signaling, emphasizing the concurrent need for controlling 
degradation to promote new cartilage formation. 
In the final chapter, key findings of this dissertation are summarized and their impact on 
future work relating to OA therapy is highlighted.    
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Chapter II: Skeletal Characterization of Smurf2-Deficient Mice and 
In Vitro Analysis of Smurf2-Deficient Chondrocytes 
 
 
1. Introduction 
 
Transforming growth factor-β (TGF-β) signaling consists of multiple secreted ligands such 
as bone morphogenic proteins (BMPs), TGF-βs, activins, inhibins, and growth and 
differentiation factors (GDFs) that regulate many cellular processes including proliferation, 
differentiation and apoptosis. Its involvement in limb formation is tightly regulated in order to 
ensure proper development and maintenance of bone and cartilage tissues268. For instance, 
TGF-β signaling is essential for joint homeostasis by promoting cartilage matrix synthesis269 and 
preventing chondrocytes from undergoing terminal differentiation270. Aberrations in the TGF-
β/BMP signaling have thus been associated with many skeletal disorders such as osteoporosis, 
heterotopic ossifications, and osteoarthritis (OA)271,272. TGF-β1 and TGF-β3 are shown to be 
diminished in human and mouse OA cartilage, respectively273,274, and transgenic mice that lose 
TGF-β signaling in cartilage recapitulate an OA-like phenotype70,275,276. 
One way in which TGF-β/BMP signaling is regulated is through the ubiquitin system. 
Ubiquitination is a post-translational modification that requires the step-wise effort of E1 
activating enzymes, E2 conjugating enzymes and E3 ubiquitin ligases. Ubiquitinated proteins 
are typically known to be targets for proteasomal degradation277; however, non-degradative 
roles have also been reported which can alter a protein’s function278 or its localization279. Smad 
ubiquitin regulatory factor 1 and 2 (Smurf1 and Smurf2) are E3 ubiquitin ligases that share high 
homology and have been shown in various cell types to regulate TGF-β/BMP signaling280. They 
inhibit TGF-β signaling by promoting the degradation of R-Smads (Smads 1, 2 and 3) and TGF-
β receptors280,281.  
Based on mouse models, Smurf1 has been implicated in various signaling pathways 
associated with bone development and function282. Smurf1-deficient mice are phenotypically 
normal at birth, but exhibit an age-dependent increase in cortical bone mass due to sensitization 
of Smurf1-deficient osteoblasts to BMP 283 . Smurf2 has been shown to be upregulated in 
cartilage explants from OA patients 284 . Using a transgenic mouse model, Wu et al. 
demonstrated that overexpression of Smurf2 in articular chondrocytes results in chondrocyte 
hypertrophy and accelerated cartilage degradation284. The potential of Smurf2 to trigger 
spontaneous cartilage degradation raises the questions as to what roles Smurf2 has during 
normal cartilage development and maintenance and whether aberrant expression of Smurf2 is 
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required for OA development. Smurf2-deficient mice285,286 are born at the expected Mendelian 
ratio with no obvious phenotypic abnormality, but have an increased incidence of tumor 
formation at 15–20 months compared to wild-type (WT). To our knowledge, there has been no 
in-depth characterization of age-dependent changes in bone and cartilage in mice with reduced 
Smurf2 expression. 
Here, we used a Smurf2-deficient mouse model generated by gene trapping285 to investigate 
whether reduced Smurf2 expression affects normal skeletal development and aging and 
whether it affects pathological conditions such as post-traumatic OA. Specifically, we 
characterized femoral cortical bone, vertebral trabecular bone, knee subchondral bone and 
knee articular cartilage of skeletally mature young (4 months old) and old (21 ± 1.3 months) 
Smurf2-deficient (MT) mice and their WT counterparts by quantitative microcomputed 
tomography (microCT) analyses and semi-quantitative histological scoring of articular cartilage 
(Figure 2.1A). In addition, we assessed the severity of OA symptoms of WT vs. MT mice in both 
age groups in response to surgical destabilization of the medial meniscus (DMM) (Figure 2.1B). 
Lastly, we utilized primary immature chondrocytes isolated fromWT and MT mice to assess how 
Smurf2 deficiency affects chondrogenic and catabolic gene expression as well as Smurf2 and 
Smurf1 protein expression in 2D culture after treatment with TGF-β3 or proinflammatory 
cytokine IL-1β. 
 
 
 
Figure 2.1 Summary of experimental design for skeletal characterization 
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2. Materials and Methods 
 
Breeding of Smurf2-deficient and WT Mice 
 
A previously reported Smurf2-deficient mouse model generated by gene trapping (on a C57BL/6 
background)285 that was developed in the Zhang lab at University of Massachusetts Medical 
School (Worcester, MA) was used for the study. WT and MT mice were generated by crossing 
mice heterozygous for the trapped Smurf2 allele. For isolation of primary chondrocytes, 
homozygous mice were bred to produce sufficient neonates of the same genotype. Adult mice 
and neonates were euthanized by carbon dioxide asphyxiation followed by either cervical 
dislocation (adults) or decapitation (neonates). All mice were housed in a fully accredited Animal 
Care facility and the animal handling and surgical procedure were approved by the University of 
Massachusetts Medical School Institutional Animal Care and Use Committee (IACUC). 
 
Bone Marrow Stromal Cells (BMSC) Isolation 
 
Hind legs were harvested from skeletally mature 4-month-old WT and MT mice. Excess 
muscles were trimmed off and one end of the tibiae and femur was cut. Adopting a published 
method287, bone marrow (BM) plugs were isolated by inserting a 25-gauge syringe needle into 
the uncut end of the long bones and flushing with serum-free α-MEM. The BM plugs were 
mechanically disrupted using a pipettor and filtered through a 70-μm mesh to remove debris. 
Red blood cells were lysed by mixing with an equal part of sterile water for <10 sec followed by 
a 1:5 dilution in 1×PBS. Cells were pelleted at 400g for 10 min and resuspended in complete 
culture medium (α-MEM with 20% hyclone FBS, 1% L-glutamine, and 1% pen/strep). The total 
cell suspension was plated on two p100 plates and media were changed twice a week. 
 
Immature Murine Articular Chondrocyte (iMAC) Isolation 
 
Following a published protocol288, iMACs were isolated from 5- to 7-day-old neonates. Cartilage 
from the knee and ankle joints was harvested, pooled, and subjected to a 60-min digestion in 
type II collagenase (Worthington) solution (3mg/mL in high glucose DMEM with 1% pen/strep) 
at 37°C under agitation. The cartilage pieces were then transferred to a diluted collagenase 
solution (0.5mg/mL) and incubated for 5–6 hours at 37°C under moderate agitation. The 
solution with residual fragments was mixed to yield a single cell suspension and filtered through 
a 70-μm nylon mesh. The chondrocytes were pelleted at 400g for 10 min, washed in PBS and 
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then resuspended in DMEM/F12 with 10% FBS. The cells were plated at a density of 2.5 x 104 
cells/cm2 and cultured for 4–6 days before subsequent in vitro treatments and analyses. The 
chondrogenic nature of these cells was confirmed by positive Alcian Blue staining for cartilage 
ECM and the expression of chondrogenic gene which decreased with multiple passaging. 
 
Whole Tissue Dissection 
 
The hind legs from 4 months old WT and MT were harvested and each leg was dissected into 1) 
muscles surrounding the tibia and femur, 2) knee joint including the patella, ligaments and the 
tibial and femoral articular ends, and 3) mid-shaft tibia and femur with intact bone marrow. The 
spleen was harvested as a control where Smurf2 is known to be highly expressed in the WT. All 
specimens were immediately frozen in liquid nitrogen, powdered using a mortar and pestle, and 
stored at -80°C until time for protein or RNA isolation. 
 
Western blot for BMSCs, iMACs, and musculoskeletal tissues 
 
Total cell lysates from Passage 0 BMSCs and iMACs were extracted using RIPA buffer (50mM 
Tris pH 7.5, 150mM NaCl, 1% Triton X, 1mM EDTA, 0.1% SDS, 0.5% Na-deoxycholate) 
supplemented with a protease inhibitor cocktail (Roche). For protein isolation from whole bone, 
joint, and skeletal muscle, powdered specimens were resuspended in RIPA. Protein lysates 
(25–60μg) were separated by SDS-PAGE mini-protean gels (Bio-Rad) and transferred to 
nitrocellulose membranes. Membranes were probed using primary antibodies against Smurf2 
(Abcam, ab53316, 1:1000), Smurf1 (Abcam, ab117552, 1:2000), Col2 (Millipore, MAB8887, 
1:2000), Sox9 (Millipore, AB5535, 1:1000), GAPDH (Sigma, G8795, 1:5000), tubulin (Sigma, 
T6074, 1:5000) and goat secondary antibodies against rabbit (Santa Cruz, 1:5000) and mouse 
(Santa Cruz, 1:10,000) IgG and then visualized using a chemiluminescent substrate (Pierce). 
 
RT-PCR for Smurf2 mRNA levels in whole bone and cartilage tissues 
 
Powdered tissues were resuspended in TRIzol reagent (Life Technologies) and vortexed at 
room temperature for 15–20 min. Insoluble components were removed by centrifugation 
(12,000g, 10 min). RNA was purified using Direct-zol RNA MiniPrep (Zymo Research) according 
to manufacturer’s instructions and RNA concentration was determined using a Nanodrop 2000 
spectrophotometer (Thermo Scientific). Total RNA (1 μg) was reverse-transcribed using 
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SuperScript III First-Strand Synthesis Kit (Life Technologies) according to manufacturer’s 
instructions. PCR reactions were conducted on a GeneAmp PCR system 2700 (Applied 
Biosystems) under the following conditions: 94°C for 3 min, followed by 35 cycles at 94°C for 20 
sec, 58°C for 30 sec, 72°C for 1 min, and a final extension at 72°C for 10 min. PCR products 
were subjected to electrophoresis on a 1% agarose gel and visualized by ethidium bromide 
staining. RT-PCR primer sequences: Smurf2 (Fwd: 5’-AACCGTGCTCGTCTCTCTTC-3’, Rev: 
5’-ATGAAGTCATTCCCCAGCAC-3’); GAPDH (Fwd: 5’-AGGTCGGTGTGAACGGATTTG-3’, 
Rev: 5’-TGTAGACCATGTAGTTGAGGTCA-3’.) 
 
Preparation of skeletal tissues for microCT and histology 
 
For analysis of knee joints by microCT and histology, hind legs were harvested from skeletally 
mature young (4 months old) and old (21 ± 1.3 month old) male mice, tied to a toothpick in a 
fully extended position, and fixed in 10% neutral buffered formalin for 2–3 days at 4°C before 
being scanned and subsequently decalcified for histology. For analysis of femoral cortical bone 
and vertebral trabecular bone, hind legs from 4 and 18 month old mice and lumbar vertebrae 
from 16 month old male and female mice were harvested and fixed in 10% neutral buffered 
formalin for 2–3 days at 4°C before being scanned by microCT and subsequently decalcified for 
histology. 
 
Quantitative MicroCT analyses 
 
All skeletal tissues were scanned on a Scanco microCT 40 scanner (Scanco Medical, 
Brüttisellen, Switzerland) at a 10-μm voxel resolution. Cortical bone analysis was performed by 
evaluating 50 slices (volume of interest/VOI) from the midshaft (10 micron spacing, flanking the 
midpoint between growth plates of the femur) for bone volume, cortical thickness, and bone 
mineral density. Vertebral bone analysis was performed on either the L4 or L5 vertebrae and the 
region of interest (ROI) was defined by the entire trabeculae within the body of the vertebra 
excluding the cortical bone. The bone volume/tissue volume (BV/TV), trabecular thickness, 
trabecular spaces, and bone mineral density were determined using Scanco’s trabecular bone 
evaluation that is based on distance transformations (Direct-No model method). For 
subchondral bone analysis, the medial and lateral condyles of the proximal tibia epiphysis were 
analyzed separately. The ROI was defined by the bone between the calcified cartilage and the 
growth plate. The bone volume/tissue volume (BV/TV), trabecular thickness, trabecular spaces, 
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and bone mineral density were calculated using the same trabecular bone evaluation method as 
the vertebrae. For subchondral bone analysis after DMM surgery, only the medial condyle of the 
tibia was evaluated and osteophytes were excluded from the ROI. 
 
Knee Histology and Semi-Quantitative Scoring of Articular Cartilage 
 
Formalin-fixed hind legs were decalcified for 14 days in 18% EDTA and frontally embedded in 
paraffin blocks. Blocks were cut using a Reichert-Jung 2030 microtome to produce 5μm thick 
sections. Sections were deparaffinized then stained with Weigert’s iron hematoxylin/fast 
green/safranin-O (Sigma). To systematically compare knee articular cartilages, a minimum of 
five equally spaced sections spanning the knee joint were analyzed using a modified published 
semi-quantitative scoring criterion 289 . Articular cartilage with loss of staining or superficial 
structural damage was referred to as mild OA (scores of 0.5 and 1), while fibrillations and 
erosions with increasing depth and width below the superficial layer and extending past the 
tidemark were referred to as moderate (scores of 2 and 3) or severe OA (score of 4). Sections 
with majority of the subchondral bone exposed or only a small portion of articular cartilage intact 
were categorized as very severe OA (scores of 5 and 6). The medial femoral and tibial articular 
cartilages of each knee section were blindly scored by 7 trained examiners. The scores from 
each examiner were averaged and the average scores for the femoral and tibial cartilage were 
plotted separately on the same graph for semi-quantitative comparisons. 
 
Surgical Induction of OA by Destabilization of Medial Meniscus (DMM) 
 
DMM, a well-established surgical model for inducing OA195, was performed on 2 month old and 
19 ± 1.3 month old male mice. Briefly, the mice were anesthetized using 2% isoflurane in 
oxygen, and the surgical site was sterilized before a medial parapatellar incision was made to 
expose the joint cavity. The meniscotibial ligament was identified and transected under a 
stereomicroscope. Joint capsule and overlying skin were sutured in layers using 7–0 PGA 
sutures. Buprenorphine (0.05mg/kg, 3 times a day) and cefazolin (20mg/kg, twice a day) were 
injected subcutaneously immediately post-operation (post-op) and for 2 more days thereafter. 
Mice were allowed to move freely in cages immediately after the operation. At 2 months post-
DMM, the mice were euthanized and their hind legs were harvested and prepared for µCT and 
histology analyses as described above. 
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Quantitative RT-PCR (qPCR) of Primary Chondrocytes 
 
iMACs were isolated from WT and MT mice as described above. Cells were seeded at 2.5 x 104 
cells/cm2 and cultured in expansion medium (5% FBS in DMEM/F12) for 4 days on tissue 
culture polystyrene (TCPS). Cells were then treated with 10 ng/mL of TGF-β3 (R&D Systems) or 
5 ng/mL of IL-1β (R&D Systems) for 24 hours. RNA was isolated, purified and reverse-
transcribed as described above. qPCR samples were prepared using Power SYBR Green 
Master Mix (Applied Biosystems) and analyzed using a 7500 Real-Time PCR System (Applied 
Biosystems). Gene expression of Sox9, Col2, Acan, Col1, MMP-3, MMP-9, MMP-13, and 
ADAMTS5 were normalized to β-actin levels. Data were plotted as fold-change relative to those 
of untreated WT. Primer sequences are summarized in Table 2.1. 
 
Table 2.1 Sequences of primers used for quantitative RT-PCR. 
 
 
 
Statistical Analysis 
 
Statistical analyses were performed using Prism (Graphpad Software, Version 6.0). MicroCT 
data were presented as the mean ± standard deviation and the statistical analyses were 
performed using 2-way ANOVA followed by Tukey’s post-hoc test. Knee histological scores 
were plotted as a dot plot with the median and interquartile range, and the statistical analyses 
were performed with either Kruskal-Wallis with Dunn’s multiple comparison test (for age and 
genotype-dependent changes) or the Mann-Whitney rank-sum test (response to DMM surgery). 
Distribution of the histological scores from post-DMM WT and MT knees were compared using 
Kolmogorov-Smirnov test. qPCR results are presented as a mean ± standard deviation of three 
separate chondrocyte isolation experiments for each genotype and the statistical analysis was 
performed using unpaired t-test for each treated and untreated condition. Quantifications of WB 
bands were normalized to WT expansion medium control and averaged among three replicates. 
A value of p < 0.05 was considered statistically significant. 
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3. Results 
 
Characterization of Smurf2 Expression in skeletal tissues 
 
To study the role of Smurf2 in skeletal tissues, we began by examining the levels of Smurf2 
expression in these tissues. The level of Smurf2 protein in knee joints, cortical bones/bone 
marrow, and skeletal muscles of C57BL/6 WT mice was undetectable compared to levels in the 
spleen by western blot (Figure 2.2A). Using RT-PCR, we confirmed that the total mRNA levels 
of Smurf2 extracted from these skeletal tissues were much lower than in the spleen, but all MT 
tissue examined showed reduced Smurf2 mRNA expression compared to WT, as expected 
(Figure 2.2B). We also examined Smurf2 expression in bone marrow stromal cells (BMSC) and 
immature murine articular chondrocytes (iMAC) isolated from MT and WT mice, and found that 
Smurf2 protein levels are significantly reduced in both MT primary cells (Figure 2.2C). 
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Figure 2.2 Smurf2 protein and gene expressions in WT (+/+) and Smurf2-deficient MT (T/T) skeletal tissues 
and primary cells. 
(A) Protein expression of Smurf2 in various skeletal tissues from healthy 4 month old male WT and MT mice. Spleen, 
where Smurf2 is highly expressed, is included as a positive control. (B) Smurf2 mRNA expression in various skeletal 
tissues compared to spleen in 4 month old male WT and MT mice. (C) Protein expression of Smurf2 in bone marrow 
stromal cells (BMSC, passage 0) isolated from 4 month old WT and Smurf2-deficient MT mice and immature articular 
chondrocytes (iMAC, passage 0) isolated from WT and MT neonates. 
 
 
Smurf2-deficient mice exhibit normal age-dependent cortical and trabecular bone 
phenotypes 
 
Using microCT, we examined changes in mid-shaft femoral cortical bone between WT 
and MT mice at 4 months and 18 months of age. Although a slight drop in bone mineral density 
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(BMD) was observed with advanced age, these changes were not statistically significant. No 
significant difference between WT and MT mice at a given age was detected (Figure 2.3A). Due 
to its high surface area to bone matrix volume ratio, trabecular bone undergoes more rapid 
remodeling and is associated with more prominent bone loss with age than cortical bone290. We 
therefore assessed the vertebral trabecular bone in 16 month old mice using microCT to reveal 
potential remodeling abnormality between genotypes. To account for the effect of estrogen 
deficiency on bone remodeling, these analyses were performed in a sex-specific manner 
(Figure 2.3B and 2.3C). Regardless of genotype, the vertebral trabecular bone of old female 
mice exhibited lower BV/TV and higher trabecular thickness and trabecular spaces than their 
male counterparts. These sex-specific differences were not statistically different between WT 
and MT mice. 
 
 
 
Figure 2.3 Age- and sex-specific cortical bone and trabecular bone analyses of WT and Smurf2-deficient MT 
mice. 
(A) Mid-shaft cortical bone analysis of male WT and MT femurs from 4 month (WT: n = 6; MT: n = 7) and 18 month 
old (WT and MT: n = 7) mice. (B) Sex-specific trabecular bone analysis of lumbar vertebrae from 16 month old WT 
and MT mice (Male: n = 7; Female: n = 5). (C) Representative 3D reconstruction of contoured vertebral trabecular 
bone. Scale bar = 500 μm. 
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Smurf2-deficient mice exhibit normal knee joint phenotype 
 
Qualitative comparison of histological sections of WT and MT knee joints did not reveal 
any gross developmental or age-related abnormalities within the growth plates, menisci, or 
synovia (data now shown). In order to characterize the structural changes in knee articular 
cartilage that would reflect spontaneous OA development with age, we adopted a published 
semi-quantitative knee histological scoring system289 and assigned each score an overall OA 
severity (Figure 2.4A). Since lateral tibial articular cartilage tends to be thinner with less distinct 
zonal architecture291, we focused our analyses on the medial side. Using this scoring system, 
we detected age-dependent changes in the articular cartilage from normal to mild OA in the 
medial tibial and femoral condyles in both the WT (p = 0.0011) and MT (p < 0.0001) mice, but 
no statistically significant difference was detected between them at a given age (Figure 2.4B). 
The main differences observed between the two age groups ranged from general loss of 
proteoglycan staining to mild superficial fibrillations as reflected by the median scores of 0.64 
(0.35–0.72) and 0.57 (0.41–0.67) in the 21 month old WT and MT groups, and 0.26 (0.14–0.36) 
and 0.14 (0.06–0.26) in the young 4 month old WT and MT groups, respectively. 
We then investigated whether age-dependent changes in the tibial subchondral bone 
were different between WT and MT. Since previous work reported differences in the medial and 
lateral compartments of the subchondral bone292 , we analyzed microCT data in these two 
compartments separately. Compared to the lateral side, the medial subchondral bone 
compartment had a higher BV/TV, trabecular thickness and BMD across both age groups and 
genotypes (Figure 2.4C and 2.4D). The age-dependent loss of trabecular bone within the medial 
compartment was also apparent as supported by the increase in trabecular spacing, from 
0.154±0.011 (WT) and 0.175±0.027 (MT) in the young group to 0.193±0.026 (WT) and 
0.229±0.036 (MT) in the old group, respectively. However, no statistically significant differences 
were detected between WT and MT mice at a given age. 
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Figure 2.4 Age-specific knee joint phenotypes of male WT (+/+) and Smurf2-deficient MT (T/T) mice. 
(A) Normal and osteoarthritic joint articular cartilage histology scoring along with representative safranin O-stained 
cartilage sections. Yellow line indicates tidemark; Black arrows denote loss of staining, fibrillations, or erosions. (B) 
Combined histology scores of femoral and tibial articular cartilage of 4 month old WT (n = 13), 4 month old MT (n = 
13), 21 month old WT (n = 11), and 21 month old MT (n = 11). (C) Representative microCT images of bone mineral 
density color mappings of mid-frontal knee sections from young and old WT and Smurf2 MT mouse knees. Red 
indicates higher BMD while green indicates lower BMD. D) Quantitative comparisons of the lateral and medial 
subchondral bone analyses between 4 month (WT: n = 9; MT: n = 11) and 21 month (WT: n = 10; MT: n = 8) WT and 
MT mice. *p<0.05. 
 
 
 
Young Smurf2-deficient mice develop milder OA in knee articular cartilage compared to 
WT mice after DMM surgery 
 
DMM is a well-established surgical-induced model of OA in mice that mimics the slow 
progression of human OA following traumatic knee injury195. To determine whether Smurf2 
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deficiency affects the pathological development and progression of OA or alters the repair 
mechanisms in response to knee injury, we performed DMM surgery on 2 month old male WT 
and MT mice and evaluated their knee articular cartilage by histological scoring after 2 months. 
Histological sections from the medial side of the DMM-operated knees revealed cartilage 
erosions extending below the superficial layer and past the tidemark in the WT mice, while 
mainly loss of proteoglycan staining and superficial fibrillations were observed in the MT DMM 
knees (Figure 2.5A). This difference resulted in a post-DMM median histological score of 1.85 
(0.91–3.80) for WT and 1.00 (0.59–1.78) for MT, both of which were significantly higher than the 
respective un-operated contralateral controls (p < 0.0001) and significantly different from each 
other (p < 0.01) (Figure 2.5B). We also observed a profound difference in the distribution of the 
post-DMM histology scores between WT and MT, which was verified using the Kolmogorov-
Smirnov test (p = 0.043). The difference in the distribution of cartilage scores between WT and 
MT knees in response to DMM is best reflected by categorizing the OA severity of each scored 
specimen (Figure 2.5C). Specifically, while all WT mice developed knee OA 2 months after 
DMM, with 69.2% of the articular cartilage exhibiting moderate (42.3%) to severe/very severe 
(26.9%) OA phenotypes, 69.2% of the articular cartilage from MT mice knees developed either 
mild OA (50.0%) or remained normal (19.2%). Only 30.8% of the MT mice exhibited a moderate 
OA cartilage phenotype at 2 months after DMM, and none exhibited severe or very severe OA 
symptoms. 
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Figure 2.5 Differential severity of knee joint articular cartilage erosions in young (4 month) and old (21 ± 1.3 
month) male WT and Smurf2-deficient MT mice after DMM surgery. 
(A) Representative images of safranin O-stained articular cartilage sections from the medial compartment of WT and 
MT knees 2 months post-DMM surgery. (B) Semi-quantitative histology scores of the femoral and tibial articular 
cartilage of DMM knees vs un-operated controls (n = 13 for 4 month; n = 11 for 21 ± 1.3 month). The average femoral 
and tibial articular cartilage scores for each joint were plotted separately on the same graph. Groups with the same 
symbol are not statistically significant (p > 0.05) based on mean ranks. (C) Distribution of DMM knee scores for WT 
and MT based on OA severity. 
 
 
Since sclerosis of the subchondral bone has been detected in mice after DMM surgery, 
we evaluated whether Smurf2-deficiency affected the degree of sclerosis. Representative 
images of WT and MT DMM knees revealed increased bone mineral density localized in the 
medial femoral condyle and the tibial plateau at 2 months after DMM (Figure 2.6A). Quantitative 
analysis of the medial subchondral compartment of the tibia (Figure 2.6B) showed an increasing 
trend in trabecular thickness in both WT and MT. The concurrent loss of trabecular space is 
more apparent in the MT mice. The changes in BMD detected before and after DMM surgery in 
either genotype was not statistically significant, likely due to the large standard deviation among 
the WT subchondral bone in response to DMM. 
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Figure 2.6 Knee joint subchondral bone analyses in 4 months old male WT and Smurf2-deficient MT mice 
upon surgical induction of OA by DMM. 
A) Representative microCT bone mineral density (BMD) color mapping of medial compartment of 4 month old male 
mice knees 2 months post DMM. White arrows = areas with increased bone mineral content; L = lateral; M = medial; 
red indicates higher BMD while green indicates lower BMD. B) Quantification of subchondral bone change in medial 
compartment of tibial plateau after DMM reflecting trends of increased BV/V, trabecular thickness and decreased 
trabecular spaces. WT: n = 9; MT: n = 11. 
 
 
Aging increases severity of OA in both WT and MT knees but the subset of mice 
exhibiting normal or mild OA is still greater in MT 
 
Since age is a risk factor for OA development, we performed DMM surgery on older (19 
± 1.3 month) Smurf2-deficient mice to examine whether the attenuated OA cartilage phenotype 
observed at 4 months may be sustained with age. Histological scores of the older knees 2 
months post-DMM revealed that aging increased the overall severity of OA symptoms for both 
WT (p < 0.05) and MT mice (p < 0.001) (Figure 2.5B and 2.5C). The median post-DMM 
histological scores for the older mice were 3.02 (2.00–4.00) for WT and 2.56 (1.32–4.32) for MT, 
but the reduction in OA severity in MT was not statistically significant (p = 0.460) based on 
mean ranks comparison. Unlike the 4 month old mice, the distribution of histological scores was 
also similar between the old WT and MT mice as verified by the Kolmogorov-Smirnov test (p = 
0.621). It is interesting to note, however, the subset of mice exhibiting normal or mild OA 
articular cartilage symptoms post-DMM at such an advanced age was still greater in the MT 
mice (27.3%) than in the WT mice (9.1%). 
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Smurf2-deficient chondrocytes display elevated chondrogenic gene expression in 2D 
culture compared to WT 
 
To examine how Smurf2 deficiency might affect chondrocyte function in a chondrogenic 
or pathological environment in 2D culture, we isolated iMACs from WT and MT mice and 
compared the gene expression of key anabolic and catabolic genes in the presence of a 
chondrogenic factor, TGF-β3, or a proinflammatory cytokine, IL-1β. MT chondrocytes showed 
trend of higher levels of chondrogenic gene expression (Sox9, Col2, and Acan) than WT with 
and without addition of TGF-β3 (Figure 2.7). In the presence of IL-1β at 5 ng/mL, an overall 
decrease in the expression of chondrogenic genes Sox9, Col2, and Acan and an increase in the 
expression of catabolic genes MMP-3, MMP-9, MMP-13 and ADAMTS5 were observed in both 
WT and MT. It is worth noting that the trend of higher levels of chondrogenic genes in MT than 
WT persisted even under the inflammatory conditions, with the higher Sox9 expression in MT 
being statistically significant. Although there was no consistent trend in the expression of 
catabolic genes between WT and MT iMACs, there was a statistically significant difference in 
MMP13 and ADAMTS5 expression between WT and MT upon IL-1β treatment. The level of 
Col1, a marker for chondrocyte dedifferentiation, was similar across all conditions between 
genotypes. We were unable to detect Col10 expression in iMACs from either genotype after 40 
cycles. 
 
 
 
 
Figure 2.7 Quantitative gene expression analyses of key anabolic and catabolic markers in WT and MT iMACs. 
Cells were cultured as a monolayer on 2D tissue culture polystyrene for 4 days and treated with either 10 ng/mL of 
TGF-β3 or 5 ng/mL of IL-1β for 24 hours. Data are reported as the mean ± standard deviation of three separate 
chondrocyte isolations for each genotype. EM = Expansion Media, *p < 0.05 (p values approaching significance are 
noted on the graph). 
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TGF-β3 and IL-1β modulates Smurf1 and Smurf2 expression in iMACs in vitro 
 
To determine whether Smurf2 and Smurf1 protein levels are perturbed in chondrogenic 
or pathological conditions, we detected their expressions in WT iMACs after TGF-β3 or IL-1β 
treatment by western blot. Treatment of WT iMACs with TGF-β3 caused a dose-dependent 
increase in Smurf2 while treatment with IL-1β resulted in a dose-dependent decrease (Figure 
2.8A). Even though the treatment of iMACs with TGF-β3 widened the difference in Smurf2 
between WT and MT, the difference in protein expression of Col2 and Sox9 between WT and 
MT was not as apparent (Figure 2.8B). Smurf1, which shares high homology with Smurf2, 
appeared slightly elevated in MT iMACs compared to WT after TGF-β3 treatment, but 
quantification of the intensities of these bands was not statistically significant (Figure 2.9). 
 
 
 
Figure 2.8 Smurf protein expression changes upon 24-h treatment of TGF-β3 and IL-1β. 
A) WT chondrocytes show dose-dependent increase of Smurf2 protein with 24-h TGF-β3 treatment and dose-
dependent decrease with 24-h IL-1β treatment. B) No compensatory increase of Smurf1 protein levels was detected 
between WT (+/+) and Smurf2-deficient MT chondrocytes (T/T) with and without treatment of TGF-β3 (10 ng/mL) or 
IL-1β (0.1 ng/mL). Type 2 collagen levels were also similar between WT and MT chondrocytes across all conditions. 
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Figure 2.9. Western blot quantification of Smurf2 and Smurf1 proteins in WT and MT iMACs. 
Protein bands for Smurf2 and Smurf1 bands were quantified and normalized to WT iMAC in expansion media (EM). 
Quantification was based on the average of three separate experiments with different WT and MT pairs. n.d. = not 
detected. 
 
 
4. Discussion 
 
In this study, we characterized bone and joint phenotypes of Smurf2-deficient mice as a 
function of age because Smurf1 and Smurf2 have been implicated in regulating bone and 
cartilage function, respectively. Using microCT and histological analyses, we compared age-
dependent changes in femoral cortical bone, vertebral trabecular bone (sex-specific), tibial 
subchondral bone, and knee articular cartilage between WT and Smurf2-deficient MT mice. We 
found that the reduction of Smurf2 expression did not impact the normal development and 
maintenance of bone and cartilage throughout adulthood, and the observed bone and cartilage 
changes as a function of age are consistent with previous reports on aged WT C57BL/6 
mice291,293,294,295. 
Since the overexpression of Smurf2 in chondrocytes was reported to trigger 
spontaneous OA284, we subjected skeletally mature 2 month old Smurf2-deficient mice to DMM 
surgery and examined whether their development of OA is mitigated compared to WT. We 
observed that at 2 months post-DMM, MT mice were less susceptible to pathological 
development of OA compared to WT. Based on our OA severity categorization criteria, the 
majority of articular cartilage from WT DMM knees developed moderate to severe OA (69.2%; 
characterized by significant cartilage fibrillations and erosions extended beyond the tidemark 
and into subchondral bone), while the majority of articular cartilage from MT DMM knees was 
normal  or developed only mild OA (69.2%). More remarkably, none of the articular cartilage 
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from MT DMM knees developed severe OA. In contrast, none of the articular cartilage from WT 
knees was normal 2 months after DMM, and a subset of them developed severe to very severe 
OA (26.9%). The presence of subchondral bone sclerosis and osteophyte formation has long 
been associated with human OA knees. However, it remains controversial whether subchondral 
bone changes are an etiology of OA or whether they reflect a bone remodeling process that 
reacts to the deteriorating overlaying cartilage 296 . From our study, we did not detect any 
significant changes in subchondral bone sclerosis (Figure 2.6) or osteophyte formation between 
genotypes by 2 months post-DMM, suggesting that the subchondral bone remodeling process 
induced by DMM is not entirely dependent on Smurf2 expression or the integrity of the overlying 
cartilage. 
Given that the impact of Smurf2 on cartilage progressed with age and that Smurf2 
deficiency has been implicated in inhibition of cellular senescence285, we questioned whether 
the protective effect of Smuf2 deficiency against OA development after DMM surgery may 
persist with age. Histological scores of the joint articular cartilage showed that aging caused 
both WT and MT mice to develop more severe OA after DMM surgery, with an increase of the 
median score for the 21 month old WT (3.02 vs. 1.85) and MT (2.56 vs. 1.00) when compared to 
4 month old counterparts. Nevertheless, we found that the subset of joint cartilage that 
remained normal or exhibited only mild OA phenotype post-DMM was still greater among old 
MT than WT, suggesting that some degree of protective effect may still persist at this age. 
Because the majority of the specimens do develop moderate to severe OA, a larger sample size 
is necessary to demonstrate the significance of this subset between old WT and MT. Altered 
biomechanics due to weight changes, impaired bone and cartilage repair, and homeostasis due 
to aging can all potentially mask the protective effect of Smurf2 deficiency on OA development. 
Overall, the ability of Smurf2 inhibition to delay, alleviate or prevent OA symptoms in the multi-
tissue compartments of the joint, particularly at advanced age, requires further investigation. 
Taking advantage of this Smurf2-deficiency mouse model, we isolated immature 
articular chondrocytes from newborn mice and asked how Smurf2 deficiency affects the 
expression of common chondrogenic and catabolic genes upon culture treatment with TGF-β3 
or IL-1β. The pro-inflammatory cytokine IL-1β is known to shift the balance of chondrocytes from 
matrix synthesis towards degradation and has been used to emulate an inflammatory OA 
environment in vitro297,298. We found that MT chondrocytes trended toward a higher mRNA level 
of chondrogenic genes including Sox9, Col2, and Acan compared to WT with and without TGF-
β3 treatment. As expected, IL-1β treatment of the chondrocytes globally suppressed 
chondrogenic genes and upregulated the catabolic genes that we examined. The general trend 
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of higher chondrogenic gene expression in the MT than WT was maintained even under 
proinflammatory conditions, with the difference in Sox9 being statistically significant and that of 
Col2 approaching significance. The differences observed between WT and MT iMACs at the 
mRNA level, however, did not translate directly to the protein level. We found no difference in 
Col2 protein expression and Sox9 protein expression was only slightly higher in the MT iMACs 
treated with TGF-β3 compared to WT. Interestingly, both Col2 and Sox9 expression seem to 
decrease after 24 hour treatment with TGF-β3 compared to untreated cells. We confirmed that 
this increase in chondrogenic gene expression was not due to differences in the degree of 
dedifferentiation between WT and MT in vitro by demonstrating that Col1 expression was similar 
across all experimental conditions. On the contrary, there was no consistent trend in the 
expression of catabolic genes examined (MMP-3, -9, -13 and ADAMTS5) between WT and MT. 
Compared to WT iMACs, MT iMACs had statistically significant lower expression of MMP3 upon 
TGF-β3 treatment, but higher expression of MMP-13 and ADAMTS5 after IL-1β treatment. In 
the absence of TGF-β3 or IL-1β, no significant differences in any catabolic genes were detected. 
Incidentally, we found that both TGF-β3 and IL-1β modulated Smurf2 levels in WT iMACs in a 
dose-dependent manner. TGF-β3 also increased Smurf1 levels, and the increase was higher in 
MT chondrocytes than in WT, suggesting a potential but weak compensatory mechanism by 
Smurf1 in Smurf2-deficient iMACs. Whether TGF-β3-induced increase of Smurf1 and Smurf2 
affects the phosphorylation of intracellular R-Smads or the stability of TGF-β receptors or other 
downstream effector proteins remain to be determined. 
Despite previous reports demonstrating Smurf proteins to modulate the TGF-β/BMP 
signaling299,300 and the importance of this pathway in bone and cartilage development301,302,303, 
the lack of an obvious skeletal phenotype in MT mice during normal development and aging as 
elucidated by this study has a few implications. It suggests that a high level of Smurf2 
expression may not be required for bone and cartilage development and that the low levels of 
Smurf2 present in the MT mice may be sufficient to maintain normal physiological activities. In 
addition, Smurf1 may have redundant functions that can compensate for the reduced Smurf2 
levels during normal development and aging, and account for the moderate and weak protection 
against OA development observed in young and old Smurf2-deficient mice, respectively. 
There are a few limitations of our study. First, it is unclear whether reduced Smurf2 
expression functions to delay the onset of OA and/or hinders its progression. We have not 
identified the exact stress signals produced by DMM that can trigger Smurf2 activity or stimulate 
its expression beyond physiological levels, which could help establish a molecular basis of how 
Smurf2 drives OA pathogenesis. Second, besides articular cartilage and subchondral bone, 
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other joint tissue compartments involved in OA pathogenesis such as synovium, muscles and 
bone marrow were not examined in this study. Third, the use of immature articular chondrocytes, 
driven by their ease of isolation, to compare the chondrogenic potential of WT and MT cells may 
not be ideal. Not only is the population of iMACs heterogenous with varying degrees of 
differentiation, but their response to exogenous growth factors and cytokines may be different 
from the chondrocytes residing in mature articular cartilage. Tissue-specific Smurf2-deficient 
cells (e.g. obtained via conditional knockouts) may be more accurate at revealing the potential 
cellular contributors within the multi-tissue joint compartment to the protective OA phenotype 
observed in MT mice after DMM. Lastly, to unequivocally establish the redundant function of 
Smurf1 and Smurf2 in chondrocytes, validation by simultaneous knock down experiments would 
be desired. 
In summary, we show that while loss of Smurf2 in mice has no physiological impact on 
bone and cartilage development and aging, its ability to attenuate OA symptoms after DMM 
surgery in 4 month old mice indicate a potential role in regulating the pathological development 
of OA. Whether Smurf2 inhibition alone is sufficient to be a therapeutic target for OA remains 
unclear since the protective effect of Smurf2 in older mice is markedly reduced compared to the 
younger age group. The enhanced chondrogenic gene expressions in MT iMACs compared to 
WT suggest a potential for greater cartilage matrix deposition, but the optimal condition to 
facilitate its translation into meaningful enhancements in cartilage regeneration remain to be 
identified. 
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Chapter III: Age-dependent Changes in the Articular Cartilage and  
Subchondral Bone of C57BL/6 Mice after Surgical Destabilization of 
Medial Meniscus 
 
1. Introduction 
 
Age is the primary risk factor for developing osteoarthritis (OA), a chronic, degenerative joint 
disease that is characterized by progressive loss of articular cartilage and subchondral bone 
changes. While joint space narrowing, subchondral bone sclerosis and osteophyte formation are 
all clinical signs of OA, the temporal nature of these changes and how they contribute to OA 
etiology are still an ongoing debate304,305. More recently, the notion that articular cartilage and 
subchondral bone should be viewed as a single unit due to their proximity and evidence of 
biomechanical and molecular signaling crosstalk has gained traction96,306,307. Osteophytes have 
also been regarded as a compensatory response to mechanical weakening of the degrading 
cartilage100, but existing evidence remains limited. Therefore, understanding how bone and 
cartilage structures change during OA progression as a function of age is essential to better 
understand OA pathology, elucidate key cellular and molecular players, as well as to develop 
disease modifying drugs. 
Murine OA models are invaluable tools for both basic and translational research due to the 
ease of manipulating mouse genome. OA can be induced in murine articular joints by 
collagenase injection308, surgical destabilization194, or non-invasive injury techniques187. Surgical 
destabilization of the medial meniscus (DMM) results in gradual deterioration of articular 
cartilage and subchondral bone changes, and is thought to recapitulate the progression of 
human OA pathology174,195. Although DMM emulates post-traumatic OA by nature, murine DMM 
models have been broadly used by many studies to identify disease-modifying OA targets such 
as FGF1309, progranulin310, IGF-II311, DKK1312, DDR2313, HIf2alpha51 and ADAMTS5314. Recently, 
our lab has shown that Smurf2-deficiency mitigates cartilage degradation following DMM 
surgery; however, this benefit is reduced with advanced age315. In order to elucidate how age 
impacts the efficacy of various therapies for DMM-induced OA, it is critical to understand age-
dependent changes in articular cartilage and subchondral bone after joint destabilization. 
Most DMM-induced OA studies entail surgery on 2–3 month old male mice and analyze their 
OA phenotypes 1–2 months later. While 2 month old mice are considered skeletally mature 
adults, their skeletal tissues continue to undergo significant changes well beyond 2 months. For 
instance, C57BL/6 mice femurs do not reach their maximum length until 6 months of age, and 
osteoporotic changes in the trabecular bones are not apparent until 6–12 month in females and 
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over 12 months in males294. Aged mice also undergo significant weight changes, where it almost 
doubles by 12 months due to body fat accumulation294. Such age-related skeleton and body 
mass changes may reflect more accurately the biochemical and mechanical environment of 
human OA joints of middle-aged and older populations. Understanding how aged mice respond 
to DMM differently can enhance the translatability of this murine model to human OA. In addition, 
young (~4 M) female mice were found to be less prone to developing OA following DMM 
compared to their male counterparts316, but whether the perceived protective effect of sex 
hormone persists over age is unclear. 
While prior human studies317,318,319 have established correlations among articular cartilage 
erosions, subchondral bone sclerosis and osteophyte formation, whether and how age impacts 
such structures in the mouse DMM OA model has not been carefully investigated. Previous 
studies that evaluated the effects of age on DMM-induced OA only examined young mice with 1 
month age difference prior to DMM291 or focused their study on differences in gene 
expressions320. This study aims to understand how different tissue compartments in the knees 
of wild-type C57BL/6 mice from different age groups respond to DMM surgery by using cartilage 
histology scoring and quantitative micro-computed tomography (microCT) analyses of 
subchondral bone plate thickness and osteophyte formation. In addition, we also evaluate 
whether female hormones continue to provide protective effects on DMM-induced OA by 
comparing joint phenotype differences between middle-aged males and females at 2 months 
post-DMM. 
 
 
2. Materials and Methods 
 
Animals 
 
Wild-type C57BL/6 mice were used in this study. The mice were divided into three age groups 
corresponding to 4 month old (4 M, male), 12 month old (12 M, male and female) and 18–22 
month old (19 M+, male; 18 M and 21 M, female) mice at 2 months post-DMM surgery. All mice 
were housed in a fully accredited Animal Care facility. All procedures and experiments were 
approved by the University of Massachusetts Medical School Institutional Animal Care and Use 
Committee (IACUC), and performed in accordance with the relevant guidelines, regulations and 
approved IACUC protocol. 
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DMM Surgery 
 
Surgery was performed on the right knee of mice at 2 months (male, n = 13), 10 months (male, 
n = 11; female, n = 11), 17–20 months (male, n = 11), and 19 months (females, n = 4) as 
previously described on page 29. 
 
Histology Analysis 
 
The operated and unoperated knees were harvested, processed for histology, and sections 
were scored as described on page 28-29. In this study, we focused our analysis on the medial 
tibial plateau since it is known to be more susceptible to damage after DMM314 and we 
confirmed that it is indeed the case even in the 19 M+ age group. Furthermore, we avoided 
femoral condyle analysis as we found that it revealed less consistent results with changes in 
cartilage and the subchondral bone due to its greater degree of rotation.  
 
microCT Analysis 
 
Mice knees from each age group (4 M male, n = 9; 12 M male, n = 8; 12 M female, n = 7; 18 M 
female, n = 3; 19 M+ male, n = 7; 21 M female, n = 3) were scanned on a microCT using 
parameters described on page 28. To determine subchondral bone plate thickness, the cortical 
bone of the medial tibial plateau was contoured to exclude the calcified articular cartilage and 
any portion that is part of an osteophyte. The thickness was calculated using Scanco’s 
trabecular bone evaluation (Direct method). Color maps of the thickness were generated from 
the contoured subchondral bone plate of the operated and unoperated knees. Only well-
demarcated osteophytes that projected outward from the subchondral bone of DMM operated 
knees were contoured and quantified for total osteophyte tissue volume (TV) and bone volume 
fraction (BV/TV). 3D reconstruction of the knees was carried out to visualize topographical 
changes on the bone surface as well as the extent of bony outgrowths as a function of age, 
gender and DMM. Quantitative microCT data were presented as mean ± standard deviation. 
 
Statistical Analysis 
 
All statistical analysis was performed using GraphPad Prism version 7.0 (La Jolla, CA). Analysis 
of the histological scores was performed using Mann-Whitney non-parametric t-test. Analysis of 
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all microCT data was performed using 2-way ANOVA and Tukey’s multiple comparisons test. P-
value < 0.05 was considered significant. 
 
 
3. Results 
 
Severity of cartilage loss after DMM surgery was exacerbated in older male mice.  
 
Cartilage histological scores of the medial tibiae from DMM-operated and unoperated 
contralateral knees of male mice from three different age groups revealed that the severity of 
OA cartilage 2 months post-DMM was significantly higher in the 12M and 19M+ group than in 
the 4M group (Figure 3.1A and 3.1B). The median histological scores of unoperated knees for 
the 4M, 12M and 19M+ groups were 0.18 (0.11–0.33), 0.33 (0–0.33) and 0.67 (0.33–0.75), 
respectively, consistent with very mild, non-structural spontaneous OA cartilage changes with 
age. The median histological score of the DMM knees in the 4M, 12M and 19M+ groups was 
1.8 (0.81–2.4), 4.2 (3.8–4.5) and 3.4 (2.2–4.7), respectively. Representative images of the 
articular cartilage in unoperated contralateral knees showed only progressive loss of safranin-
O/fast green staining but minimal structural change with age, with superficial fibrillations only 
observed in some of the 19M+ group. By contrast, the articular cartilage of DMM-operated 
knees showed increasing severity of cartilage erosion beyond the tidemark with age 
(Figure 3.1B). 
 
 
 
 
Figure 3.1 Age-dependent changes in articular cartilage degradation of male mice 2M post-DMM  
(A) Histological score of the tibial articular cartilage of unoperated and DMM operated knees of male mice from 
different age groups. Individual scores are plotted along with median score and interquartile range. *p-value < 0.05, 
****p-value < 0.0001; (B) Representative safranin-o/fast green stained histological sections of the articular cartilage of 
unoperated and DMM operated knees of male mice from different age groups. 
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Subchondral bone plate thickening after DMM surgery was greater in older male mice 
 
The subchondral bone plates of operated knees increased in thickness 2 months after 
DMM surgery compared to unoperated contralateral knees regardless of age (Figure 3.2A). The 
difference in thickness between the operated and unoperated knee was significant in the 12 M 
and 19 M+ groups. The 4 M group followed a similar upward trend, but the increase was not 
statistically significant. In the unoperated control knees, the thickness of the subchondral bone 
plates was comparable across all age groups. Color maps of the subchondral bone plate 
thickness confirmed that the 4 M age group exhibited a similar range of thickness between 
operated and unoperated knees, but in the 12 M and 19 M+ groups, the thickness significantly 
increased post-DMM (Figure 3.2B). 
 
      
 
 
Figure 3.2 Age-dependent changes in subchondral bone plate thickness of male mice 2M post-DMM   
(A) Quantification of tibial subchondral bone plate thickness of DMM operated and unoperated contralateral knees of 
male mice from different age groups. *p-value < 0.05, **p-value < 0.01; (B) Representative color maps of subchondral 
bone plate thickness of DMM operated and unoperated contralateral knees from each age group. Color map legend 
is scaled to the maximum thickness detected in the 19 M+ group. A = anterior, P = posterior, M = medial, and 
L = lateral. 
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Bone volume fraction of osteophytes after DMM was significantly higher in older (19 M+) 
male mice 
 
Osteophytes were detected on all of the DMM operated knees regardless of age, 
although two knees from the 4 M age group showed only superficial bony outgrowths and were 
not quantified. None of the unoperated knees showed signs of osteophyte formation, except for 
one knee in the 19 M+ age group. Quantification of the osteophyte total tissue volume (TV) 
revealed a trend of increasing size with age, but this was not statistically significant (Figure 3.3A, 
left). The bone volume fraction (BV/TV) of osteophytes was significantly higher in the 19 M+ 
group compared to the other age groups, while no difference in bone volume fraction was 
observed between the 4 M and 12 M age groups (Figure 3.3A, right). Representative histological 
images of the osteophyte, as demarcated by a black dashed line, showed a progressive 
increase in osteophyte size and disappearance of cartilaginous regions and marrow-like cavities 
with age (Figure 3.3B). 3D reconstruction of the microCT images allowed visualization of the 
bone surface topographical changes between DMM operated and unoperated knees (Figure 
3.3C). The 4 M unoperated tibia had an even textured surface and a distinct ossification groove 
that marks the perichondrial ring of the growth plate. In contrast, the 4 M DMM operated knee 
showed extensive superficial bone thickening that obscured the ossification groove. A few 
roughened patches (indicated by unfilled arrows) were also observed in the distal femur. In the 
12 M group, the ossification groove was less visible in the unoperated tibia than the younger 
mice while the DMM operated tibia showed extensive bone thickening, prominent rough patches 
(especially in the distal femur, indicated by unfilled arrows) and appearance of distinct bone 
projections (indicated by filled arrows). In the 19 M+ group, signs of rough patches were 
observed both before and after DMM while far more pronounced osteophyte projections were 
observed post DMM. 
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Figure 3.3 Age-dependent changes in osteophyte size and quality of male mice 2M post-DMM 
(A) Total tissue volume (TV) and bone volume fraction (BV/TV) of contoured osteophytes in DMM operated knees of 
male mice from different age groups. ***p < 0.001, ****p < 0.0001; (B) Representative safranin-O/fast green stained 
histological sections of the DMM operated knees in male mice from different age groups, with osteophytes contoured 
by dotted lines; (C) Representative 3D reconstructed microCT images revealing distinct surface topographical 
changes of the knee post-DMM in male mice from different age groups. Open red arrows indicate areas of superficial 
roughening and/or thickening of bone surface that were not observed in the unoperated knee. Filled red arrows 
indicate osteophyte protrusions away from subchondral bone surface which were more prominent in the 19 M+ age 
group. Scale bar = 1 mm. 
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Female mice developed milder OA post-DMM compared to males in the 12 M age group 
 
Female mice from the 12 M group developed milder OA than their male counterparts 
(Figure 3.4A). The median histological score of the articular cartilage from unoperated female 
knees was 0.25 (0.08–0.42) compared to a score of 0.33 (0.00–0.33) in the males, reflecting 
normal cartilage structures for both sexes (Figure 3.4B). In the DMM operated female knees, 
the median histological score was 1.3 (1.0–1.8) compared to the operated male knees of 4.2 
(3.8–4.5). Histological images showed that the articular cartilage damage was primarily limited 
to superficial fibrillations and loss of safranin-O/fast green staining in the 12 M female post-DMM, 
while the male operated knees showed more severe cartilage erosions down to the calcified 
cartilage (Figure 3.4B). The degrees of subchondral bone sclerosis between 12 M male and 
female DMM operated knees were also very different despite similar bone plate thickness in the 
unoperated knees. No statistically significant increase in subchondral bone plate thickness was 
observed in the females while significant thickening was observed in the males after DMM 
(Figure 3.4C). Color maps of bone thickness showed a distinct localization of the thickened 
region in the subchondral bone plate of the male operated knee while the spatial variation of 
subchondral bone plate thickness between unoperated and operated knees remained similar in 
the 12 M female (Figure 3.4D). Finally, smaller osteophytes were detected in 12 M female DMM 
operated knees (TV = 0.028 ± 0.014 mm3) compared to males (TV = 0.096 ± 0.047 mm3) (Figure 
3.4E), but the bone volume fraction of the osteophytes were comparable between the two sexes 
(Figure 3.4F). Histology also confirmed smaller osteophytes in the female DMM knees, which 
were also characterized by the presence of marrow-like cavities (Figure 3.4G). 3D 
reconstruction of the microCT images detected visible projections of osteophytes extending out 
from the subchondral bone (Figure 2.4H, indicated by filled arrows) in DMM operated males but 
not in the females. 
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Figure 3.4 Comparison of different tissue compartments of the joint between 12M male and 12M female mice 
2M post-DMM   
(A) Histological score of the tibial articular cartilage from unoperated and DMM operated knees of male vs. female 
mice from the 12 M age group. Individual scores are plotted along with median score and interquartile range. ***p-
value < 0.001, ****p-value < 0.0001; (B) Representative safranin-O/fast green stained histological sections of the 
articular cartilage of unoperated and DMM operated knees of male vs. female mice from the 12 M age group; (C) 
Quantification of tibial subchondral bone plate thickness of DMM operated and unoperated contralateral knees of 
male vs. female mice from the 12 M age group. **p-value < 0.01; (D) Representative color maps of subchondral bone 
plate thickness of DMM operated and unoperated contralateral knee of male vs. female mice from the 12 M age 
group. Color map legend is scaled to the maximum thickness detected in the 19 M+ age group. A = anterior, 
P = posterior, M = medial, and L = lateral; (E) Total tissue volume (TV) and (F) bone volume fraction (BV/TV) of 
contoured osteophytes in DMM operated knees from male vs. female mice from the 12 M age group. **p < 0.01; (G) 
Representative safranin-O/fast green stained histological sections showing the presence of osteophyte (dashed line) 
in the DMM operated knees in male vs. female mice from the 12 M age group; (H) Representative 3D reconstructed 
microCT images showing distinct surface topographical changes of the knee post-DMM in male vs. female mice from 
the 12 M age group. Open red arrows indicate superficial roughening and/or thickening of bone surface. Filled red 
arrows indicate osteophyte protrusions away from subchondral bone surface. Scale bar = 1 mm. 
 
 
With advanced age, female mice showed signs of severe OA and subchondral bone 
changes post-DMM 
 
Of the female mice at 21 M (n = 4) that underwent DMM surgery, two showed signs of 
severe OA cartilage with scores of 5.0 and 6.0 while the other two had scores of 1.2 and 2.2, 
which were comparable to the scores from the female 12 M group post-DMM (Figure 3.5A and 
3.5B). The difference in subchondral bone plate thickness with and without DMM surgery was 
also significant for female mice in the 21 M (n = 3) group but not in the 12 M (n = 7) or 18 M (n = 3) 
groups (Figure 3.5C). Color mapping showed that the overall subchondral bone changes with 
and without DMM were very mild compared to male counterparts (Figure 3.5D) and that the 
difference observed in the 21 M group was a result of severe osteoporosis in the unoperated 
control (Figure 3.5E). The sizes of the osteophytes detected in the DMM-operated knees were 
comparable across all female age groups (Figure 3.5F), but the BV/TV of the osteophytes was 
highest post-DMM in the 18 M group (Figure 3.5G). 
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Figure 3.5 Age-dependent changes in different joint structures of female mice 2M post-DMM 
(A) Histological scores and (B) representative safranin-O/fast green stained histological sections of the tibial articular 
cartilage from unoperated and DMM operated knees of female mice from the 12M and 21M age groups. Individual 
scores are plotted along with median score and interquartile range. *p < 0.05; (C) Quantification and (D) 
representative color maps of tibial subchondral bone plate thickness of DMM operated and unoperated contralateral 
knees of female mice from the 12M, 18M and 21M age groups. * p-value < 0.05, **p-value < 0.01; Color map legend 
is scaled to the maximum thickness detected in the male 19M+ age group. A = anterior, P = posterior, M = medial, 
and L = lateral; (E) µCT images of longitudinal cross sections of DMM operated and unoperated contralatesral knees 
of female mice from 12M, 18M and 21M. Open arrows indicate areas of osteoporosis and closed arrow indicates 
region of enhanced bone remodeling after DMM surgery. (F) Total tissue volume (TV) and (G) bone volume fraction 
(BV/TV) of contoured osteophytes in DMM operated knees of female mice from the 12M, 18M and 21M age group. *p 
< 0.05. 
 
 
4. Discussion 
 
Multiple tissue compartments within the knee undergo significant structural changes 
during OA development. Using C57BL/6 mice from 3 age groups, we determined that articular 
cartilage and subchondral bone respond to DMM differently with age. The DMM surgery, 
popularized by Glasson et al.195, is considered a minimally invasive surgery that mimics human 
OA following meniscal injury. However, most murine OA studies that perform DMM do not 
adequately address age-related perturbations in joint mechanics or cellular processes. Results 
from this study reaffirm that age is an important factor in dictating how various compartments in 
the mouse joint respond to DMM-induced OA and should be considered in determining the 
translatability between murine OA models and human OA. 
Subchondral bone plate sclerosis and articular cartilage degeneration are both hallmarks 
of mouse314 and human OA321. We showed that in male mice, the thickening of DMM-induced 
subchondral bone plate accompanied increased severity of degradation in the overlying 
cartilage. However, between 12 M and 19 M+ groups, we did not observe significant differences 
between the degrees of cartilage degradation and subchondral bone thickening. Interestingly, 
although the 12 M and 19 M+ groups both weighed significantly more than the 4 M group, no 
significant further increase in body weight from 12 M to 19 M+ was detected (data not shown). 
Whether the observed age-related changes can be attributed to altered joint mechanics (driven 
by weight gain or reduced physical activity) or by age-related cellular metabolism and function 
requires additional studies. Given the need for more reproducible murine models to study OA322, 
our results suggest that performing DMM surgery on middle-aged male mice (12 M group) could 
be advantageous in producing more uniform and reproducible OA phenotypes than in younger 
mice (2 M group). The 19 M+ group also developed more severe cartilage degradation post-
DMM than the 4 M group, but the histology scores were not as uniform as the 12 M group. 
 57 
Possible reasons include the wider age range (19 to 22 months at time of analysis) within this 
group and other unexplored comorbidities that accompany advanced age. 
Osteophyte formation was detected in all DMM operated knees regardless of age, but 
the size and shape varied. Among the three age groups, the size of the osteophyte post-DMM 
trended up with age but the increase was not significant (Figure 3.3A, left). The size323 and 
direction324 of the osteophyte have been associated with the degree of cartilage erosion, but this 
correlation was not evident from our data. No significant differences in the size or bone volume 
fraction of osteophytes was observed between 4 M and 12 M age groups where the greatest 
difference in cartilage and subchondral bone plate changes were detected. The direction of the 
bony outgrowths was also confined to the horizontal axis and never in the vertical axis, which is 
common in advanced human OA. Overall, our data with aged male mice do not support a strong 
correlation between the extent of osteophyte formation/remodeling and the degrees of articular 
cartilage erosion or subchondral bone plate thickening. This finding is in line with previous 
observations that osteophytes can develop in the absence of overt cartilage damage100,106 and 
in some animal models is visible a few days after joint injury101. Nevertheless, it is still possible 
that cartilage and the subchondral bone plate affect osteophyte development through soluble 
factors. Interestingly, we found that the bone volume fraction of the osteophytes in the 19 M+ 
age group was significantly higher than those in the younger age groups, consistent with more 
extensive bone remodeling/faster bone turnover reported within more mature osteophytes105,107. 
The appearance of central ossification coupled with fewer cartilaginous regions and marrow-like 
cavities in the 19 M+ osteophyte was also consistent with more extensively remolded bone 
found in later stages of osteophyte development107. While higher bone turnover in the 
subchondral bone has been associated with advanced stages of human OA325,326,327, further 
studies are necessary to understand the relationship among different stages of osteophytes and 
OA progression. 
Sex hormones play a significant role in OA severity in the murine DMM model, where 
young 4.5 M males develop more severe OA than age-matched females316. Given the more 
consistent OA phenotype in 12 M males, we examined whether sex differences in DMM-induced 
OA severity persisted at this age. We found that at 12 M, female mice continue to develop 
milder OA compared to age-matched males, characterized by less articular cartilage 
degradation, less subchondral bone sclerosis, and smaller osteophytes. This milder OA in the 
12 M females also reflects the same association between cartilage erosion and subchondral 
bone plate thickening found in males. Since C57BL/6 female mice produce litters up to 15 
months of age328, the amount of circulating estrogen in 12 M females may be sufficient to still 
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protect against more severe OA in spite of their increasing osteoporosis risks and weight 
gains294. It should be noted, however, the weight factor cannot be ruled out from the observed 
sex-specific differences as 12 M female mice weighed significantly less than 12 M male 
counterparts (data not shown). 
Although not the focus of this study, examination of the contralateral unoperated joint 
controls revealed that spontaneous OA due to age was very mild in nature. The age-induced 
OA changes were characterized with mainly progressive loss of safranin-O staining of the 
articular cartilage but no significant structural perturbations (superficial fibrillations only observed 
in some of the 19 M+ group). We also did not observe significant changes in subchondral bone 
with age except for the very old (21 M) females where a reduction in subchondral bone mineral 
density consistent with osteoporosis was observed. 
There are several limitations in this study. First, we validated the efficacy of our DMM 
procedure with sham operation controls (opening and closing of skin and joint capsule) in the 
2 M aged groups prior to the study where OA was only found in DMM-operated but not sham-
operated joints (comparable to non-operated control), but such validation was not performed in 
the other older age groups. It should be noted, however, that the limited literature320 on relatively 
old mice demonstrated no difference between sham and unoperated control in 12 M male mice. 
In addition to articular cartilage and subchondral bone, synovial inflammation also plays a role in 
OA development116 and is also age-dependent291. Detecting markers of inflammation in the 
synovial fluid or in the serum could provide insight into age-related difference in the degree or 
onset of joint inflammation. Finally, the observation that females were still protected from DMM-
induced OA at 12 M begs the questions as to whether such protection diminishes in even older 
females. Since this was not the initial focus of our study, we used only a limited number of aged 
female mice to preliminarily evaluate the structural joint changes in much older (18 M and 21 M) 
females. We observed severe cartilage erosions in some 21 M females while others showed 
only mild cartilage erosions similar to those seen in the 12 M age group. This suggests that the 
protective effect of sex hormone may have started to decrease at 21 M. It was only in the 21 M 
female group that we observed significant differences in subchondral bone plate thickness 
between DMM operated and unoeprated knees, which we attribute to the severe thinning of the 
subchondral bone prior to DMM due to osteoporosis. For future comprehensive studies 
investigating the role of sex hormone in OA development in old female mice, it would be 
valuable to extend the examination beyond 2 months post-DMM, as others have shown that sex 
hormone protection against DMM-induced OA in younger females could subside after 12 
weeks329. 
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In conclusion, we showed that the increasing severity of DMM-induced cartilage 
degradation as a function of age was accompanied with more pronounced subchondral bone 
plate thickening and, to a lesser extent, the increasing size of osteophytes. Our findings support 
previous work 330  that utilizes non-invasive monitoring of subchondral bone changes as an 
accurate method for evaluating OA severity longitudinally. Future work combining contrast-
enabled microCT quantitation331 of cartilage changes with subchondral bone plate thickness 
changes could help establish better temporal correlations between these two structures during 
OA development. Our study supports the view332 that age is an important factor in dictating 
structural changes (accelerated cartilage loss coupled with subchondral bone plate sclerosis 
and enhanced osteophyte maturation) post-DMM. Accordingly, we suggest that therapeutic 
effects of potential disease modifying OA targets observed in young adult mice using DMM-
induced OA should also be validated in older mice. Our data also suggest that DMM-induced 
OA in older 12 M mice is more reproducible and may be more relevant than 4 M mice for 
identifying and translating potential disease modifying OA targets to human therapy. 
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Chapter IV: Anionic and Zwitterionic Residues Modulate the Stiffness 
of Photo-crosslinked Hydrogel and the Cellular Behavior of 
Encapsulated Chondrocytes 
 
1. Introduction 
 
Articular cartilage is a highly specialized and organized tissue that lines the ends of long 
bones and is integral to the function of all diarthrodial joints. Not only does it provide superior 
lubrication for moving bones but it also possesses the mechanical properties to resist 
compressive and tensile forces that are essential for weight-bearing and movement. The unique 
extracellular matrix (ECM) of cartilage is comprised of an interpenetrating network of collagen 
and negatively charged proteoglycans and contains only one cell type, chondrocytes. Due to its 
avascular and aneural nature, articular cartilage has very limited regenerative capability. 
Defects in articular cartilage as a result of traumatic injury fails to heal properly and promote the 
formation of a mechanically inferior fibrocartilage, predisposing an individual to develop 
osteoarthritis (OA) and to undergo total knee arthroplasty ten years earlier than the average 
population 333 , 334 . Various surgical techniques204 have been employed to promote hyaline 
cartilage regeneration, including osteochondral autograft/allografts, microfracture, and 
autologous chondrocyte implantation, but none has unequivocally demonstrated long-term 
efficacy in delaying the onset of OA.  
With promising clinical results 335 , 336  and recent FDA approval 337 , matrix-assisted 
autologous chondrocyte implantation (MACI) has gained traction for focal articular cartilage 
lesion repair, and has inspired more biomimetic scaffold designs to promote ECM deposition. 
Ongoing strategies have focused on engineering  synthetic polymer scaffolds to recapitulate the 
biochemical and biomechanical environment of native ECM338. For instance, incorporation of 
natural hyaluronic acid and chondroitin sulfate in synthetic hydrogels have frequently been 
employed to stimulate chondrocyte differentiation and promote cartilage matrix production of 
encapsulated progenitor cells339,340,341,342. The bioactivity of these macromolecules has been 
attributed to their interaction with cell surface receptors343 as well as their ability to sequester 
and enrich secreted endogenous soluble factors within the tissue microenvironment through 
electrostatic interactions344,345. The prochondrogenic effects of these biomacromolecules on 3D 
encapsulated chondrocytes and stem cells, however, are difficult to delineate as their 
incorporation into the synthetic matrices often perturb other properties, such as crosslinking 
efficiencies and swelling ratios, making it difficult to isolate one effect from the other. Controlled 
covalent incorporation of small molecule chemical moieties into a synthetic hydrogels has 
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therefore been explored as an alternative for regulating the fate / metabolism of encapsulated 
cells.  
Previous work346, 347 from the Anseth group have shown that covalent incorporation of 
hydrophobic tert-butyl and phosphate residues in hydrogels promoted adipogenic and 
osteogenic differentiations of encapsulated stem cells, respectively. Zwitterionic residues, which 
possess equal numbers of positive and negative chargesand are overall charge neutral, have 
the ability to interact with oppositely charged ionic solutes or oppositely charged epitopes of 
proteins. We previously showed that zwitterionic residues, when presented in 3-D crosslinked 
hydrogels, are able to template robust mineralization by attracting oppositely charged precursor 
ions348 , 349  or dynamically retain and release growth factors for scaffold-guided bone tissue 
regeneration350. Whether synthetic hydrogels functionalized with zwitterionic residues may be 
exploited for cartilage tissue engineering, however, remains unclear. 
Another distinct feature of the articular cartilage tissue microenvironment is the osmotic 
swelling pressure and stiffness imposed by the anionic proteoglycans embedded within the 
collagen network. Aggrecan, the predominant chondroitin sulfate proteoglycan in articular 
cartilage, is primarily responsible for affording cartilage its resistance to compression. 
Specifically, it is the fixed negative charges from sulfated and carboxylated residues of 
aggrecan that attract counter ions and water, resulting in high osmotic pressure and resistance 
to compression 351 , 352 , 353 . Photo-crosslinked polyethylene dimethacrylate (PEGDMA)-based 
hydrogel scaffolds are highly hydrophilic and have been widely explored for cartilage tissue 
engineering. However, augmenting their mechanical properties to better resist compressive 
forces and fluid flow have been largely limited to shortening PEG chain lengths, increasing 
covalent crosslinking content, or increasing the overall weight fraction of the polymer354,355,356. 
These modifications, however, also inevitably alter the overall swelling behavior and nutrient 
transport of the synthetic network. Chemical modification of PEGDMA hydrogels aimed at 
increasing the stiffness of the hydrogel scaffold without increasing polymer content or 
significantly perturbing swelling behavior remains largely unexplored. 
We hypothesize that strengthening mechanical properties of photo-crosslinked 
PEGDMA hydrogels could be accomplished via covalent incorporation of small molecule anionic 
or zwitterionic residues without altering overall polymer content or swelling behavior. In addition, 
we hypothesize that the incorporation of these residues within a 3D matrix at an appropriate 
content could help maintain a suitable microenvironment for cartilage matrix deposition by 
encapsulated chondrocytes. To test this hypothesis, we photo-polymerized 0%, 5% or 10% 
sulfonate (negatively charged) or sulfobetaine (zwitterionic) functionalized methacrylates (SPMA 
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and SBMA, Figure 4.1A) with varying contents of PEGDMA while maintaining the overall 
polymer fraction the same. We then investigated their swelling, mechanical properties as well as 
the viability and chondrogenic matrix production of encapsulated chondrocytes. The non-
degradable nature of the photo-crosslinked PEGDMA network was chosen to eliminate the 
confounding factor of hydrogel degradation so that the effect of chemically-modified 
microenvironment may be more readily delineated. 
 
 
 
2. Materials and Methods 
 
Polyethylene glycol dimethacrylate (PEGDMA) Synthesis 
 
Synthesis of PEGDMA was adapted from a previously described method357. Briefly, 20g of 
polyethylene glycol (PEG) with molecular weight of 6,000 Dalton (Sigma) was refluxed at 120 °C 
to remove water. After cooling, the PEG was dissolved in 150 mL of toluene and 4 molar 
equivalent of anhydrous trimethylamine (Sigma) and methacryloyl chloride (Aldrich) were added. 
The mixture was reacted at 35 °C overnight under argon. Triethylamine salt was removed by 
filtration and the PEGDMA product was precipitated in ice cold diethyl ether (Fisher). Finally, the 
product was further purified by removing lower molecular weight side products/reagents via 
dialysis against water at room temperature using a 2,000 Dalton MW cutoff membrane prior to 
freeze drying. The 1H NMR spectrum of PEGDMA was consistent with previously published 
work357.  
 
Hydrogel Preparation 
 
Stock solutions of PEGDMA, 3-sulfopropyl methacrylate potassium salt (SPMA, Sigma) and [2-
(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (SBMA, Sigma) were 
prepared in PBS to a final concentration of 10% (w/v). All hydrogels were prepared by adding 
0.05% of VA-086 (Wako) into solutions of PEGDMA and either 0%, 5% or 10% of the SPMA or 
SBMA stock solution to maintain a final polymer content of 10% (w/v). For mechanical testing, 
hydrogel solutions (200uL) were photo-crosslinked in an 8 mm diameter Teflon mold under 
365nm irradiation for 10 min, then fully equilibrated in PBS at room temperature prior to testing. 
For cell-laden hydrogels, 500,000 cells were mixed with 50 µL of the polymer cocktail and 
photo-crosslinked in Teflon molds under 365-nm irradiation for 10 min to achieve a final cell 
encapsulation density of 107 cells/mL. 
 63 
 
Equilibrium Volume Swelling Ratio (ESRv) 
 
Crosslinked hydrogels were equilibrated in PBS for 72 h with gentle agitation on an orbital 
shaker at room temperature. The height, h, and diameter, d, of the swelled hydrogel was 
measured using digital calipers and the final swelled volume (Vs) was calculated as hπ(d/2)2. 
ESRv of each hydrogel in PBS was determined by the formula ESRv=(Vs-Vd)/Vd×100% where Vd 
is 50 µL for all formulations. 
 
Immature Murine Articular Chondrocyte (iMAC) Isolation 
 
iMAC was harvested from wild-type C57BL/6 neonates (4-6 days old) as previously described 
on page 26. 
 
Human OA Chondrocytes (hAC) Isolation 
 
Discarded tissues from osteoarthritic patients (age 50-70) undergoing total knee arthroplasty 
were collected and stored in ice cold PBS supplemented with penicillin/streptomycin until 
processing shortly after. Using a sterilized razor blade, structurally intact articular cartilage from 
the femoral condyles was shaved off and minced into tiny pieces. The cartilage pieces (3-5 g) 
were transferred to a 50-mL conical tube with type II collagenase solution (1mg/mL or 300U/mL) 
and digested overnight at 37 °C on a rotator. Any residual cartilage fragments were removed by 
filtration through a 70-µm nylon mesh and the cell suspension was plated at a cell density of 
25×103/cm2. Cells were cultured until 80% confluency before trypsinization and encapsulation in 
hydrogel. Only passage 1 hACs were used in the study. 
 
Cell Culture Media 
 
Cell-laden hydrogels were cultured at 37 °C with 5% CO2 in either expansion medium (EM) or 
chondrogenic medium (CM). EM consisted of 10% FBS (Gibco) and 1% penicillin/streptomycin 
(Corning) in high glucose DMEM (Invitrogen) while CM consisted of high glucose DMEM 
supplemented with 40 µg/mL L-proline (Sigma), 100 µg/mL sodium pyruvate (Sigma), 1% 
insulin-transferrin-selenous acid mixture (B&D Bioscience), 100 nM dexamethasone (Sigma) 
and 10 ng/mL TGF-β3 (R&D systems). Media were changed three times per week. 
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Mechanical Testing 
 
The unconfined compressive behavior of each hydrogel formulation (n=3) was examined under 
strain-controlled mode on a DMA800 (TA Instruments) equipped with a submersion 
compression fixture. Each hydrogel specimen was submerged in PBS (pH 7.4) and compressed 
three times to 30% strain at a rate of 20%/min under ambient conditions (20°C). The 
compressive moduli for each hydrogel were calculated at the strain ranges of 5-10% and 15-
20%. 
 
 
Metabolic Activity of Encapsulated Chondrocytes 
 
The metabolic activity of encapsulated chondrocytes in each hydrogel formulation (n=3) was 
examined using cell counting kit-8 (CCK-8, Dojindo), which reflects the dehydrogenase activity 
within viable cells. At each time point, CCK-8 reagent was added to the cell culture medium and 
incubated for 4 h. Colorimetric analysis of the media was performed at 450nm using a Multiskan 
FC microplate photometer (Thermo Scientific).   
 
Live/Dead Staining of Encapsulated Chondrocytes. 
 
Viability of encapsulated chondrocytes was examined using a live/dead staining kit (Molecular 
Probes). Staining of the cell-laden 3D constructs was performed according to manufacturer’s 
instructions with working solutions of 2-µM calcein AM and 1-µM EthD-1. The stained hydrogels 
were placed on a glass bottom dish and imaged using a TCS SP5 II (Leica) confocal 
microscope. The composite image was created by overlaying 21 images acquired at 5-µm 
intervals along the z-axis. 
 
Histochemical staining for GAG 
 
Cell-laden hydrogels retrieved from culture were fixed with 10% neutral buffered formalin 
overnight, serially dehydrated with ethanol and embedded in glycol methacrylate and sectioned. 
Each 5-µm section was stained by toluidine blue to assess the production of sulfated GAG and 
at least 2 sections, 100 µm apart, were examined for each construct.  
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Immunofluorescence Staining for extracellular matrix proteins 
 
Cell-laden hydrogels retrieved from culture were fixed by 10% buffered formalin overnight and 
then washed thrice in 1% BSA in PBS. Primary antibody against type II collagen (Millipore, 
MAB8887, 1:200) or type X collagen (eBioscience, 14-9771-80, 1:200) was added to the 
hydrogels and incubated at 37 °C for at least one hour with mild agitation. Negative controls 
were incubated in PBS without primary antibodies. The hydrogels were washed thrice again 
with 1% BSA in PBS. Alexa 488-conjugated goat secondary antibody against mouse IgG 
(Molecular Probes, 1:200) was added for incubation at 37 °C for 1 hr. Hydrogels were then 
washed thrice in 0.1% BSA in PBS before being stained with DAPI reagent (Invitrogen) 
according to manufacturer’s instructions. The stained 3D hydrogels were placed on a glass 
bottom dish and imaged by confocal microscope (Leica) as described above. 
 
Statistical Analysis 
 
One-way ANOVA with multiple comparisons was performed using Prism (GraphPad, version 7) 
to determine the statistical significance between modified vs. unmodified PEGDMA hydrogel 
formulations (for swelling ratio, compressive modulus, quantification of encapsulated albumin-
FITC and CCK8 quantification at each time point), with p-value less than 0.05 considered 
significant.  
 
 
3. Results 
 
Covalent incorporation of anionic or zwitterionic residues into PEGDMA hydrogel 
significantly enhanced the hydrogel stiffness without perturbing the swelling ratio  
 
Percentage weight fractions of polymers in photo-crosslinked hydrogels are known to 
affect their compressive moduli and swelling behavior. We sought to isolate the effect of 
covalently incorporated anionic or zwitterionic residues on the physical and biological properties 
of PEGDMA by maintaining the total weight fraction of the polymer solution. Specifically, we 
kept the total polymer fractions constant at 10% (w/v, in PBS containing 0.05w/v% of radical 
initiator VA-086) by lowering the amount of PEGDMA when 5 or 10wt% of anionic SPMA or 
zwitterionic SBMA was added (Figure 4.1A). There was no statistically significant difference in 
equilibrated volume swelling ratios (ESRv) between any anionic or zwitterionic hydrogels and 
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the unmodified PEGDMA or among the modified hydrogels (Figure 4.1B). The equilibrated 
weight swelling ratios (ESRw) of the modified hydrogels were also statistically comparable to 
that of the unmodified PEGDMA (14.8 ± 0.4) except for 10% SPMA, which was 13.2 ± 0.1 (p < 
0.05) (data not shown). In contrast to the unchanged swelling behavior, the compressive moduli 
of all modified hydrogels were found to significantly increase as the content of covalent 
incorporation of SPMA or SBMA increased (Figure 4.1C). At the lower compressive strain range 
of 5-10%, compressive moduli of 5% SPMA and 10% SPMA were found to be 205% and 423%, 
respectively, relative to unmodified PEGDMA; whereas those of the 5% SBMA and 10% SBMA 
were increased to 168% and 250%, respectively, relative to unmodified PEGDMA. At the 10% 
incorporation content, the stiffening effect that the SPMA (16.8 ± 6.6 kPa; p < 0.0001) and 
SBMA (10.0 ± 0.03 kPa, p < 0.05) residues imposed on the PEGDMA hydrogel (4 ± 0.2 kPa) 
was statistically significant. At the higher compressive strain range of 15-20%, the stiffening 
effect of the covalent incorporation of both the anionic and zwitterionic residues became even 
more pronounced, with compressive moduli of 5% SPMA (16.7 ± 0.4 kPa, p < 0.0001) and 10% 
SPMA (29.4 ± 1.2 kPa, p < 0.0001) nearly 3 and 5 times of that of PEGDMA (5.9 ± 0.3 kPa), 
respectively. The compressive moduli of 5% and 10% SBMA hydrogels were also increased to 
9.9 ± 1.0 kPa and 14.4 ± 1.5 kPa (p < 0.001), respectively.  
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Figure 4.1. Formulations, swelling and compressive behaviors of modified vs. unmodified PEGDMA 
hydrogels.  
(A) Pictorial representation of chondrocytes encapsulated in anionic SPMA and zwitterionic SBMA-modified 
PEGDMA hydrogel network; (B) Volume swelling ratios (ESRv) of various hydrogel formulations in PBS (pH 7.4). (C) 
Unconfined compressive moduli of various hydrogels submerged in PBS (pH 7.4) at strains of 5-10% and 15-20%. *p 
< 0.05, ***p < 0.001, ****p < 0.0001 compared to unmodified PEGDMA (n=3) 
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iMACs encapsulated in SPMA hydrogels showed more pericellularly localized 
proteoglycan and reduced type II collagen expressions in both expansion media and 
serum-free chondrogenic media cultures. 
 
GAG secretion by iMACs encapsulated within hydrogels was visualized using toluidine 
blue staining over the course of 10-week culture in expansion medium (10% FBS). While iMACs 
encapsulated in all the hydrogels showed progressive increases in GAG matrix secretion over 
time, the staining patterns were quite different (Figure 4.2A). In the SPMA hydrogels, the purple 
pericellular GAG stains were darker and more compact, while those in the unmodified PEGDMA 
and SBMA hydrogels were more diffuse and penetrated the surrounding hydrogel matrices. 
Both the 5% and 10% SPMA hydrogels also showed background staining with toluidine blue as 
a result of electrostatic absorption of the positively charged dye by the sulfonated residues of 
SPMA. The GAG production by encapsulated iMACs in serum-free chondrogenic medium was 
not as robust as in the expansion medium except for those encapsulated in the 10% SPMA 
construct, which showed similar intense but compact pericellular GAG secretion (Figure 4.2B). 
Immunofluoresence staining revealed that type II collagen expression by encapsulated iMACs 
was reduced in the stiffer SPMA hydrogels, with those in 10% SPMA showing the lowest 
expression (Figure 4.3C). The degrees of chondrocyte hypertrophy, as measured by type X 
collagen expression, were minimal in all iMAC-laden hydrogel constructs. 
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Figure 4.2. ECM production by iMAC in modified vs. unmodified PEGDMA hydrogels.  
Toluidine blue-stained histological sections of iMACs encapsulated in various hydrogels and cultured in (A) expansion 
medium for 2, 4 and 10 weeks and in (B) serum-free chondrogenic media for 2 and 4 weeks. Scale bar = 100 µm (C) 
Immunofluoresnce staining for type II and type X collagen (green) of iMAC-laden hydrogels cultured in expansion 
medium for 4 weeks. Nuclei were stained with DAPI (blue). Scale bar = 100 µm. 
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iMACs encapsulated in SPMA hydrogels exhibited reduced metabolism, but not viability, 
compared to SBMA hydrogels and unmodified PEGDMA hydrogels  
 
Metabolic activity/proliferation of the encapsulated iMACs within each hydrogel 
formulation was examined using the CCK-8 reagent at various time points. During the first week 
of culture in expansion medium, encapsulated iMACs were metabolically active and underwent 
rapid proliferation, with those encapsulated in unmodified PEGDMA and those modified with 5 
or 10% zwitterionoic SBMA residues proliferating equally well. However, iMACs encapsulated in 
the 5% and 10% SPMA gave statistically significant lower CCK8 absorbance readings 
throughout the eight weeks of culture compared to all other formulations (Figure 4.3A and 4.3B). 
Live/dead cell staining confirmed that the reduced CCK-8 absorbance reading detected within 
the anionic SPMA formulations was not due to increased cell death, but rather reduced cellular 
proliferation/metabolism (Figure 4.3C). In all hydrogel formulations, the cell proliferation leveled 
off during the first two weeks of culture, followed by a slow decline in viable cells. At 8 weeks of 
culture, reduction in CCK-8 absorbance reading was only significant in the 10% SPMA 
hydrogels compared to all others.  
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Figure 4.3 Metabolic activity and cell viability of iMACs in modified vs. unmodified PEGDMA Hydrogels.  
(A) Representative images of iMAC-laden hydrogels after 4 h incubation with CCK8 reagent at various time points in 
culture. (B) CCK8 quantification of metabolically active cells. **p < 0.01, ***p < 0.001, ****p < 0.0001 (n=3), compared 
to unmodified PEGDMA at each time point. (C) Live/Dead staining of the iMAC-laden hydrogels at day 1, 7 and 28. 
Scale bar = 250 µm. 
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Human OA chondrocytes (hAC) encapsulated in 10% SPMA hydrogels showed 
reduced/more compact pericellular proteoglycan secretion when cultured in 
chondrogenic medium. 
 
To determine if the effect of SPMA hydrogels on encapsulated iMACs translates to 
human cells, we isolated hAC from discarded human OA cartilage. In contrast to iMACs, hACs 
encapsulated within these hydrogels underwent more robust ECM deposition in serum-free 
chondrogenic medium than those cultured in expansion medium containing 10% FBS (Figure 
4.5A and 4.5B). In chondrogenic medium, the extracellular matrix production of hACs was 
significantly upregulated, resulting in intense and diffused pericellular GAG staining in the 
unmodified, zwitterionic SBMA-modified and 5% SPMA-modified PEGDMA. But in the 10% 
SPMA-modified hydrogels, GAG secretion by hACs was more pericellularly localized (Figure 
4.5B). The GAGs secreted by hACs appear to diffuse more readily into the surrounding 
hydrogel matrices than those secreted by iMACs. 
 
 
Under chondrogenic conditions, hACs encapsulated in PEGDMA modified with 5% and 
10% SPMA and 10% SBMA remained viable but secreted less type II collagen.  
 
The secretion of type II and type X collagens by hACs within various hydrogels was 
detected using immunofluorescence staining. Type II collagen secretion was the lowest in the 
presence of 10% SPMA and 10% SBMA modifications (Figure 4.4C). The type II collagen 
staining was also reduced and appeared more localized around the cell and cell clusters in the 
5% SPMA-modified hydrogels compared to the unmodified or 5% SBMA-modified hydrogels. 
The secretion of type X collagen, a marker of chondrocytes hypertrophy, was minimal across all 
formulations after 4 weeks of culture. 
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Figure 4.4 ECM production by hAC in modified vs. unmodified PEGDMA hydrogels.  
Toluidine blue-stained sections of hACs encapsulated in various hydrogels and cultured for 4 weeks in (A) expansion 
medium (10% serum) or (B) serum-free chondrogenic medium. Scale bar = 100um. (C) Immunofluoresence staining 
for type II and type X collagen (green) of hAC-laden hydrogels after 4-week culture in serum-free chondrogenic 
medium. Nuclei were stained with DAPI (blue).  Scale bar = 100 µm. 
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4. Discussion 
 
The fixed negative charge density of proteoglycans provides cartilage tissue with the 
necessary osmotic pressure to withstand compressive forces and limit the expulsion of water. 
While native glycosaminoglycans such as chondroitin sulfate are often incorporated into the 
design of cartilage-mimicking hydrogel scaffolds, studies aimed at understanding the effects of 
fixed charges on both the mechanical properties of the hydrogel and the matrix protein 
synthesis of encapsulated chondrocytes are lacking. Our study demonstrates that covalent 
incorporation of small anionic (sulfonate) or zwitterionic (sulfobetaine) chemical residues into 
non-ionic hydrophilic PEGDMA hydrogel, while maintaining overall polymer content and swelling 
behavior, can enhance its compressive modulus. In addition, the incorporation of anionic 
residues can also elicit changes in type II collagen secretion by the encapsulated chondrocytes 
and how readily the secreted proteoglycans diffuse into the surrounding hydrogel matrices. 
While previous studies358,359 have shown that sulfonating polymers can affect the storage 
modulus of the biomaterial, the effect of charge incorporation could not be decoupled from the 
simultaneous change in its swelling behavior. By maintaining the overall polymer weight fraction 
at 10% (w/v) across all formulations, we were able to keep the volume swelling ratios (ESRv) 
consistent across all hydrogels despite the increase in anionic or zwitterionic residues and the 
decrease in covalent crosslinking density (due to reduction in PEGDMA). The incorporation of 5 
and 10% anionic and zwitterionic residues enhanced the compressive modulus of PEGDMA 
hydrogels in a SPMA and SBMA content-dependent manner.   
In comparison, SPMA incorporation was more effective in enhancing hydrogel stiffness than 
SBMA incorporation, likely due to more pronounced net electrostatic repulsions among the 
anionic residues.  The incorporation of zwitterionic residues, which are thought to behave like 
PEG in terms of anti-fouling effects, was also able to enhance the compressive moduli of 
hydrogels compared to unmodified PEGDMA, although to a lesser extent than SPMA residues. 
The  positive and negative ions in PBS solution are known to disrupt the physical crosslinks 
formed by dipole-dipole interactions of zwitterionic residues360. This influx of oppositely charged 
ions into the zwitterionic SBMA-modified hydrogels could be sufficient to create an enhanced 
osmotic pressure beyond that in the unmodified PEGDMA hydrogel.  
Freshly isolated iMACs can undergo robust cartilage matrix protein syntheses in expansion 
medium and are useful for detecting environmental perturbations presented by encapsulating 
hydrogels. In 10% SPMA hydrogels, the GAG staining pattern by iMACs were found to be less 
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diffusive and more confined to the pericellular region compared to other formulations, 
suggesting that the cells were either secreting less GAGs or that the secreted GAGs were 
effectively sequestered within the pericellular space by the electrostatic repulsion of sulfonate 
groups in the surrounding hydrogel matrices.  
Due to potential difference in dynamic protein sequestration among these hydrogels, we 
also assessed how chondrogenic growth medium, which contains a low dose of TGF-β3 but no 
FBS, might impact the matrix production of iMACs within these hydrogels. Interestingly, in 
serum-free chondrogenic medium, we observed a strong reduction in matrix production from 
iMACs across all the formulations except for 10% SPMA where the GAG staining pattern were 
comparable to that obtained in expansion medium. This suggests that iMAC matrix synthesis is 
highly dependent on serum concentrations, but that the presence of SPMA residues could help 
desensitize iMACs to reduced nutrient content in their local environment. This apparent 
“shielding” effect may in part be attributed to the higher osmotic pressure in SPMA hydrogels 
effectively slowing water and nutrient exchange. Published reports have shown that increasing 
stiffness by way of increasing synthetic matrix crosslinking density inhibits encapsulated 
chondrocytes’ matrix production through a reduction in cellular metabolism355,361. Our CCK-8 
results also confirmed that the metabolic activity of iMACs within the stiffer  5% and 10% SPMA 
hydrogels was reduced (although proliferation within the first week was observed) compared to 
those in SBMA-modified or unmodified PEGDMA hydrogels. The molecular mechanisms by 
which these two distinct stiffening modalities modulate the matrix production of encapsulated 
cells remain to be elucidated. While we observed a general reduction in type II collagen matrix 
production in 10% SPMA hydrogels compared to other formulations, we still observed a 
progressive increase in GAG secretion during 10 weeks of culture. Unlike iMAC, hACs 
encapsulated within the SPMA or SBMA modified hydrogels produced more cartilage matrix in 
serum-free chondrogenic medium than in expansion medium, supporting fundamental 
phenotypic differences between these two primary chondrocytes. Nevertheless, the 10% SPMA-
modified hydrogel exerted a similar effect on encapsulated hACs by reducing type II collagen 
secretion but with limited effect on GAG secretion. The GAG secreted by hAC diffused more 
readily through the 10% SPMA-modified hydrogels, suggesting that the size or charge density of 
GAGs produced by human OA chondrocytes may be different from those produced by iMACs. 
In addition, we also detected differences in type II and type X collagen secretion in 5% SPMA 
and SBMA hydrogels compared to unmodified PEGDMA hydrogels, suggesting that the 
metabolic activities of hACs could be tuned by altering the local concentrations of these 
chemical moieties.   
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Overall, observations from this study support covalent incorporation of small molecule 
anionic sulfonate and zwitterionic sulfobetaine residues in sufficient density within PEGDMA 
hydrogel as a means to enhance the stiffness of the synthetic matrix and the resident time of 
encapsulated proteins. Stiffer hydrogel resulting from higher content anionic SPMA residue 
incorporation appear to reduce the metabolic activity of encapsulated chondrocytes analogous 
to what have been observed with the stiffer substrates derived from highly photo-crosslinked 
systems362,363,364,365.  Whether the magnitude of differences observed between sulfonate and 
sulfobetaine modifications in this study can be generalized to other anionic and zwitterionic 
modifications (e.g. carboxylate vs. carboxybetaine, phosphate vs. phosphobetaine) remains 
determined. Future work should also focus on mechanoregulation of cellular function within 
these synthetic environment with/without dynamic loading, optimizing the spatial presentation of 
these chemical cues, and implementing them within a degradable hydrogel system.. Given the 
significant difference in stiffness among our hydrogels under higher strains, dynamic culture 
would likely reveal more profound differences in chondrocyte behavior that are not detectable 
under static conditions. A previous study 366  also showed that dynamic loading affects 
chondrocyte matrix production differently in a neutral versus charged environment. It is also of 
interest to investigate how the spatial distribution of charges within synthetic hydrogels (e.g. 
anisotropically presented or clustered charges emulating the densely packed chondroitin sulfate 
in native cartilage367) may affect the magnitude of their impact on cellular behavior. Finally, 
temporal control over the degradation of the synthetic matrix is necessary to enable neotissue 
integration in a timely manner.   
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Chapter V:  Discussion and Future Perspectives 
 
1. Summary of Key Findings and Significance of Dissertation Work 
 
The goal of this dissertation was to investigate two strategies that could advance therapies 
for delaying the onset or progression of OA. The first strategy was to determine whether Smurf2 
is a viable target for DMOADs. To do this, Chapter II aimed at determining whether Smurf2 had 
a role in modulating skeletal tissues under normal development and aging or under a 
pathological condition such as OA. Primary chondrocytes deficient in Smurf2 were also 
characterized to determine if any gain of function could be applied towards cell-based therapy 
for cartilage regeneration. The second strategy was focused on chemical modification of 
synthetic hydrogels in order to enhance their function for cartilage tissue engineering. 
Specifically, Chapter IV aimed at incorporating anionic and zwitterionic chemical residues into a 
PEGDMA hydrogel to improve both its mechanical and chondroinductive properties. 
 
 
Smurf2 Deficiency Results in Normal Bone Phenotype 
 
The extensive skeletal characterization of WT and Smurf2-deficient MT mice performed in 
Chapter II suggests that Smurf2 inhibition in bone and cartilage does not cause abnormal 
skeletal development and aging. This may be attributed in part to the low expression of Smurf2 
in skeletal tissue compared to other organs. It should be noted that other mouse models with 
complete knockout of Smurf2278 also did not report any skeletal abnormalities. Unlike the 
Smurf1-deficient mice283, which saw a compensatory increase in Smurf2 levels, we did not 
detect any compensatory increase of Smurf1 expression in Smurf2-deficient tissues and cells, 
suggesting a less critical role of Smurf2 in maintaining skeletal homeostasis. 
A recent paper published in Nature Communications claims that Smurf2 knockout results in 
a bone loss phenotype, which they attribute to increased receptor activator of nuclear factor 
kappa-B ligand (RANKL) expression in osteoblasts, driving osteoclastogenesis368. Their result of 
trabecular bone loss in the lumbar vertebrae at 12 weeks (~3 months) was in stark contrast to 
the lack of phenotype in our Smurf2-deficient vertebrae even at 16 months. If any correlation 
between the two mouse models exists, the bone loss should have been more apparent with age. 
Although the authors attribute the difference in phenotype to residual levels of Smurf2 
expression in our gene trap model, we have not been able to detect any Smurf2 protein in the 
skeletal tissues of our Smurf2-deficient mice.  
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Smurf2 Deficiency Attenuates OA Development in Young Mice but not Old Mice 
 
Chapter II also showed that systemic knockdown of Smurf2 slowed the progression of 
cartilage destruction in the knees of young mice after DMM surgery. This modulatory effect 
indicates that Smurf2 could very well be a potential target for DMOADs. However, the 
attenuated protection of Smurf2 deficiency in older mice after DMM does raise concerns about 
its efficacy in human disease, where advanced age is often a factor. Because DMM surgery is 
not typically performed in older mice, and no correlation to human disease has been established, 
proper interpretation of these results is difficult without additional studies. Unfortunately, during 
the course of our investigation, we were unable to accurately define the protective mechanism 
behind Smurf2 deficiency.   
 
Chondrogenic Potential of Smurf2-deficient and WT iMACs 
 
Since we observed less cartilage degradation in the Smurf2-deficient mice compared to 
WT, we focused our attention to characterize Smurf2-deficient chondrocytes. We resorted to 
using immature articular chondrocytes in order to obtain enough primary cells for testing but 
testing chondrocytes isolated from skeletally mature mice may ultimately be more revealing. 
Even though we detected some differences in chondrogenic gene expression between WT and 
MT, we could not appreciate significant functional difference at the cellular level. Proliferation, 
monolayer dedifferentiation, and proteoglycan production in 2D and 3D culture were 
comparable between WT and MT iMACs. 
Since Smurf2 appears to be involved in pathological and not physiological states, 
characterizing Smurf2-deficient primary cells in vitro is a challenge due to the inability to fully 
recapitulate the OA pathological state. While we focused on IL-1 stimulation as a surrogate for 
OA pathology, it is possible that other catabolic stimuli and/or temporal control of the 
proinflammatory cytokine may be more effective for revealing functional differences between 
WT and MT chondrocytes.  Although we were unable to attribute the protective role of Smurf2-
deficiency to articular chondrocytes, we cannot rule out the possibility that they may still play an 
indirect role in mediating disease progression in vivo. 
 
 
Age and Gender Modulate Joint Response to OA induction by DMM in Mice 
 
Due to the earlier finding of a difference in cartilage protection between young and old 
Smurf2-deficient mice after DMM, Chapter III investigated in detail how aging affects different 
 79 
joint structures in response to DMM-induced OA. Our findings show that cartilage degradation, 
subchondral bone sclerosis, and osteophyte development are accelerated with age in the male 
mice. The effect of age is less apparent in females because the female sex by itself confers 
resistance to DMM-induced OA. Nevertheless, more severe OA eventually develops in females 
at very advanced age (21 months).  
The DMM mouse model of OA remains a popular tool for understanding OA pathology and 
identifying potential disease modifying targets. Our findings bring attention to the need of 
choosing the appropriate gender and age for the DMM model. By performing DMM in both 
young and older transgenic mice, the threshold for identifying effective and powerful disease 
modifying targets can be raised and potentially eliminate false positive results. In other words, 
therapeutic targets that grant protection to OA in aged mice can most likely overcome some 
age-induced impairment and be more effective than targets that only confer protection in young 
mice, which has been current practice. One might argue that DMM in aged mice results an 
irreversible progression of OA, in which no disease modifying agent could exist, but such a 
hypothesis can only be verified through repeated studies and validation of the ideal age range at 
which to perform DMM.   
 
 
Hydrogel Stiffness derived from Covalent Incorporation of Anionic Residues Modulates 
Chondrocyte Matrix Production 
 
In Chapter IV, we showed that incorporation of small anionic or zwitterionic residues in a 
bioinert hydrogel increased its compressive modulus in a dose-dependent manner. The 
increase in stiffness of the hydrogel, at higher content, however, caused a reduction in cellular 
metabolism and reduced collagen production. These results indicate that improving mechanical 
properties of hydrogel scaffolds through chemical modification will also affect chondrogenesis of 
encapsulated cells. Although previous studies have shown that stiff 2D and 3D matrices, 
produced from highly crosslinking polymers, impair chondrogenesis, our study shows that 
stiffness derived from increased osmotic pressure will also produce a similar effect. Finally, 
whether it is the scaffold material stiffness, the proteoglycan-rich pericellular matrix or the 
osmotic pressure that predominates in modulating the chondrogenesis of encapsulated cells 
requires further investigation. 
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2. Future Directions 
 
Is Smurf2 a target for DMOAD? 
 
Based on our investigation performed in this dissertation, the question as to whether Smurf2 
is a viable target for DMOAD remains unanswered. The cellular player responsible for OA 
protection still needs to be identified. Using intraarticular injections of Smurf2 siRNA or lentivirus 
containing Smurf2 shRNA is a way of determining whether localized reduction of Smurf2 in WT 
mice can confer the same OA protection as Smurf2-deficient mice. In addition, a combination of 
Smurf1 and Smurf2 siRNA could also address concerns about the inefficiency of Smurf2 alone 
to modulate OA pathogenesis. If localized suppression of Smurf2 is effective at modifying OA 
progression, it would exclude involvement of other systemic factors and favor the involvement of 
tissues located within the joint. At that point, inducible knockout of Smurf2 from specific joint 
structures may be most effective at identifying the key cellular players. 
Another fundamental question that needs to be addressed is how Smurf2 expression or 
activity is altered during OA development. Based on the low expression of Smurf2 under 
physiological conditions, it appears that OA should at minimum cause an upregulation of Smurf2 
in order to induce non-physiological ubiquitination activity. Even though our attempts to monitor 
changes in Smurf2 expression in vivo were unsuccessful, immunohistochemical staining of 
DMM joints at different stages of OA development could reveal where and how Smurf2 
expression was changing. While not a direct correlate, an increase in the 
ubiquitination/proteosomal activity have been implicated in DMM-induced OA. Radwan et al.199 
showed that subcutaneous injection of a proteosomal inhibitor, MG132, in mice protected 
against DMM-induced OA. Nevertheless, whether Smurf2’s major functions in skeletal tissues is 
along the ubiquitin-proteosome pathway needs further clarification. 
 
 
Do Different Modalities of Inducing Stiffness Affect Chondrocyte Mechano-sensing? 
 
Our work incorporating charged anionic or zwitterionic residues demonstrates an alternative 
way of inducing stiffness in hydrogels without altering covalent crosslinking density or swelling 
behavior. Although these different methods for increasing scaffold stiffness resulted in similar 
chondrocyte behavior, it is worthwhile to investigate whether the mechanotransduction 
pathways involved are also the same. Recent reports have described the Yes-associated 
protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) as the main nuclear 
regulators of mechanical stimulus exerted by ECM stiffness and cell shape369. The link between 
YAP localization to the nucleus was also demonstrated in rat chondrocytes subjected to a highly 
 81 
crosslinked stiff matrix370. Therefore, we can potentially assess whether hydrogels containing 
anioinic residues can also induce YAP localization to the nucleus. 
To determine whether the suppression of matrix synthesis caused by the stiffer hydrogel 
is reversible, we would need to incorporate anionic residues into a degradable system. 
Hydrogels with tunable degradation rates, like the one developed in our lab371, could potentially 
be used to assess the reversibility of osmotic pressure-induced suppression of matrix synthesis. 
The reversibility of such a phenotype would open up the possibilities of a scaffold-mediated 
matrix synthesis while still providing an initial construct for mechanical support.  
 
 
Additional Studies Involving Chemically Modified Synthetic Hydrogels 
 
Chemical modification of a synthetic hydrogel is an underappreciated strategy for 
cartilage tissue engineering. The emphasis on a biomimetic scaffold entices many researchers 
to rely on incorporating native biomacromolecules into their tissue engineered constructs. 
However, such strategies are poorly controlled and do not facilitate clear understanding of cell-
material interactions. While the use of purely synthetic scaffolds is a reductionist approach and 
can lead to oversimplification of the complexity of native tissue, it allows for finer tuning of 
modifications and a more direct interpretation of causality. Our use of anionic and zwitterionic 
chemical residues was aimed at understanding how these chemical moieties affected both the 
physical property of the scaffold and the behavior of encapsulated chondrocytes. In our system, 
we found that mechanical stiffness seemed to exert a dominant negative effect on encapsulated 
chondrocytes. To determine whether the anionic or zwitterionic moieties themselves have a 
direct impact on chondrocyte function, the stiffness of the material will have to be normalized. 
However, this will eventually lead to introducing more crosslinking density in the weaker 
hydrogels or reducing the anionic content in the stiffer gels, both of which can conflict with the 
goal of the study. Another study design that examines the specificity of chemical moieties is to 
compare a variety of anionic functional groups or with different charged densities. 
Even though our study focused on differentiated chondrocytes, it may be worthwhile to 
assess how chondrogenic differentiation of stem cells might be affected within these constructs. 
There is plenty of evidence to suggest that chondrogenic differentiation of stem cells is affected 
by matrix stiffness372,373, while the potential of small chemical moieties to direct stem cell fate in 
the absence any other growth factors has also been reported346. To decouple these competing 
factors, one strategy would be to reduce the chemical crosslinking density in order to counter 
the increased stiffness from incorporation of anionic or zwitterionic residues. 
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Finally, utilizing other parameters such as dynamic compression or hypoxia to stimulate 
chondrogenesis may reveal additional synergistic effects not otherwise seen in our investigation. 
Due to differences in compressive modulus among the hydrogel formulations, dynamic 
compression should be tested in both force-controlled and strain-controlled modes. 
 
 
3. Concluding Remarks 
 
The rising burden of OA has placed a lot of pressure on researchers to come up with an 
effective DMOAD. Over the years, investments in basic science research have revealed a 
tremendous amount about mechanisms governing OA pathophysiology and potential 
therapeutic targets. Despite a slower transition, increasing efforts have also been focused on 
identifying the source of OA pain in order to design better drugs for symptomatic management 
and to improve patients’ quality of life. Clinical research has also advanced in the analysis of 
structural changes in the joint using MRI and will pave the way for phenotype OA subgroups 
based on imaging and other known risk factors. The work described in the dissertation provides 
a fraction of the knowledge needed to advance new OA therapies, but they are rooted in 
identifying a new therapeutic target, establishing better correlation between animal OA model 
and human disease, and improving scaffold-assisted delivery of cells and therapeutics for 
cartilage repair. Ultimately, the success of new OA therapies will rely on the comprehensive 
efforts from basic scientists, clinicians, and physician scientists to implement translation 
research that is directed at clinical needs but grounded in our mechanistic understanding of OA 
pathology.  
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